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ABSTRACT 
 
This non-experimental, retrospective, descriptive and correlational study investigated 
adherence to antiretroviral drugs among HIV positive patients at Mpilo Central Hospital 
in Bulawayo Zimbabwe.  Data among 118 patients was extracted from clinic registers 
and patient facility held medical records to determine level of adherence to ART using 
pharmacy refills (a non-immunological adherence parameter) and compared to CD4 cell 
count ( an immunological adherence parameter). 
 
Adherence levels obtained in this study using pharmacy refills was low (62.7%) and a 
relatively high non-adherence level of 37.3%.  The pharmacy refill adherence level 
obtained was comparable to CD4 cell count adherence level of 64.6% (as indicated by a 
50% CD4 cell count gain). These findings would seem to indicate the need for more 
education on the importance of adherence and further the need for better adherence 
monitoring systems. 
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CHAPTER 1 
 
ORIENTATION TO THE STUDY 
 
1.1 INTRODUCTION 
 
The World Health Organization (WHO) defines adherence as the extent to which an 
individual’s behaviour when taking medications changes in accordance to 
recommendations by the health care provider (WHO 2003:3).  Because HIV is a lifelong 
disease, ARV drug adherence requires lifestyle and behavioural changes, accompanied 
by strict observation of taking the drug dosage as prescribed and at prescribed times or 
intervals (WHO 2003:97,100). Studies have shown that successful treatment outcomes 
by ARV drugs depend on achieved levels of adherence (Nachega, Hislop, Dowdy, 
Chaisson, Regensberg & Maartens 2007:570, 571).  While 100% adherence to 
medication for any disease being  treated is the best practice, taking treatment 
regimens to chronic ailments is difficult (Martin, Cacho, Codina, Tuset, Lazzari, 
Mallolas, Mirό, Gatell & Ribas 2008:1263).  
 
By the end of December 2009, an estimated 3.9 million people were receiving 
antiretroviral (ARV) drugs in sub-Saharan Africa; representing a 37% coverage rate for 
the region (WHO 2010b:53). In Zimbabwe, 218,589 people were on HIV treatment by 
the end of 2009, which was an increase from an estimated 148,144 in 2008 (WHO 
2010b:55).  The rapid expansion of these programmes was happening in environments 
of programmatic challenges such as running out of drugs, lack of access and or 
unavailability of services and political and economic crises; all factors that contribute to 
non-adherence to ARV drugs (Sanjobo, Frich & Fretheim 2008:138; Veenstra, 
Whiteside, Lalloo & Gibbs 2010:11-12; Zuurmond 2008:4). 
 
Due to the high rate of HIV replication, high adherence levels are required for effective 
and sustained virologic suppression of the virus (Bisson, Rowh, Weinstein, Gaolathe, 
Frank & Gross 2008b:108; Ferguson, Donnelly, Hooper, Ghani, Fraser, Bartley, Rode, 
Vernazza, Lapins, Mayer & Anderson 2005:349; Nachega, Hislop, Dowdy, Lo, Omer, 
Regensberg, Chaisson & Maartens 2006:83-84; WHO 2003:95).  For HIV, it is generally 
recommended that adherence levels greater than 95% be achieved (Harrigan Hogg, 
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Dong, Yip, Wynhoven, Woodward, Brumme, Brumme, Mo, Alexander & Montaner 
2005:342-346; Nachega  et al 2007:564; Wood, Hogg, Yip, Harrigan, O’Shaughnessy & 
Montaner 2004:267) even though there are some studies that have documented viral 
suppression with lower adherence levels (Nachega et al 2007:570).  Unlike other 
chronic diseases, non-adherence to ARVs for HIV has major public health implications 
because of the emergence of drug-resistant viruses that can be transmitted to others 
and in the process diminish future treatment options at population level (Peltzer, Friend-
du Preez, Ramlagan & Anderson 2010:1; Veenstra et al 2010:1; Vervoort, Borleffs, 
Hoepelman & Grypdonck 2007:271).  
 
Although there are several methods found to be useful in measuring adherence to  HIV 
medications (Chalker, Wagner, Tomson, Laing, Johnson, Wahlström & Ross-Degnan 
2010:159-160; Mills, Nachega, Buchan, Orbinski, Attaran, Singh, Rachlis, Wu, Cooper, 
Thabane, Wilson, Guyatt & Bangsberg 2006b:683-684; Nachega et al 2007:565,571), 
adherence to lifelong treatment regimens is difficult to measure (Chalker et al 
2010:159).  While CD4 cell count and viral load assays are objective parameters used 
in monitoring efficacy and effectiveness including adherence and or treatment failure to 
HIV, these tests are not widely available in resource poor settings.  Other methods to 
measure adherence that have been found to be useful include pill counts, pharmacy 
refills, patient self-report and medication event monitoring systems (MEMS) (Bisson et 
al 2008b:109; Nachega et al 2007:565,571; Bangsberg 2008:S274-S275). These 
parameters however tend to be more subjective and in most resource poor settings 
MEMS are not easily available (Lyimo, Van den Boogaard, Msoka, Hospers, Van der 
Ven, Mushi & De Bruin 2011:2). In assessing or measuring adherence, it is important to 
note that there are factors that contribute to a patient’s ability or inability to take their 
medications as prescribed.  These facilitating or impeding factors can be socio-
demographic, behavioural or provider associated (Muyingo, Walker, Reid, Munderi, 
Gibb, Ssali, Levin, Katabira, Gilks, Todd & the DART Trial Team 2008:474; Peltzer et al 
2010:2; Sanjobo et al 2008:139; Skovdal, Campbell, Nhongo, Nyamukapa & Gregson 
2011:302, 309; WHO 2003:103; Zuurmond 2008:4).  As part of on-going monitoring and 
evaluation of ART interventions, it is important to have simple, reliable public health 
tools to monitor adherence. Because data is collected and kept at the health facility 
offering ART, pharmacy refill data is the adherence-measuring tool proposed 
(Bangsberg 2008:S274; Nachega et al 2006:82-84; Nachega et al 2007:565).  This 
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method can be used on routinely collected data to evaluate current or existing 
adherence levels to ART.   
 
1.2 BACKGROUND INFORMATION ABOUT THE RESEARCH PROBLEM 
 
The ART programme was launched by the Ministry of Health and Child Welfare 
(MOHCW) in 2004. Making ART accessible to all those who need it became a priority 
for the government of Zimbabwe.  ART access was scaled up from 5 learning sites in 
April 2004 to 337 sites with an estimated 219 409 (55% coverage) HIV infected patients 
both adults and children being on ART by the end of 2009 (UNAIDS 2012:30). 
According to WHO, Zimbabwe recorded a 48% increase in ART coverage rate between 
2008 and 2009 (WHO 2010b:55) and the coverage grew from 55% in 2010 to 79.7% by 
end of 2011 (UNAIDS Global AIDS response progress report 2012:31).  
  
Critical to the success of the ART intervention, is adherence.  Adherence to ART is 
important in order to maintain viral suppression, increase CD4 cell count, lengthen 
effectiveness of drug regimens and prevent development of HIV drug resistance.  HIV 
drug resistance is a serious public health concern because of the risk of transmission of 
resistant viral strains.  Overall good adherence to ART is important because it ultimately 
reduces and or prevents morbidity and mortality related to HIV. Adherence to ART is an 
important early warning indicator (EWI) for HIV drug resistance (HIVDR) hence the 
need for monitoring ART levels and to have in place the strategies for assessment and 
evaluation of adherence to ART. It is important for ART programme planners and 
implementers not to measure their success through the number of people receiving ART 
at a given time but also take into account their patients' successful compliance to 
treatment. The virologic efficacy of ART, or ‘good adherence’, is better achieved if 
patients stick to their treatment regimen for 95% of the time (Nachega et al 2007). 
 
In Zimbabwe, Muyingo et al (2008:468-475) assessed adherence using drug 
possession ratio and pill counts among patients in a highly controlled clinical 
trial.  Findings from this study showed that overall in the first year, 93% of the patients 
achieved ≥95% adherence.  Further analysis however showed that only 49% of the 
patients achieved ≥95% adherence at every clinic visit. .  Patients enrolled in the same 
study by (Muyingo et al 2008:474) were provided with transport and clinical care for 
free. Pill count was assessed at the health facility during a scheduled visit.  The 
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accuracy of the pill count method therefore depended heavily on the trustworthiness of 
the patient.  Some patients in efforts to not disappoint the health care worker and also to 
assure that more medication is dispensed have been reported to dispose of excess 
doses ahead of these scheduled clinic visits (Osterberg & Blaschke 2005:488-489), 
thereby inflating the adherence levels.  The same study also reported 90% patient 
retention in care, which was high and may not have been a true reflection of a public 
health setting in Zimbabwe. 
 
1.3 THE RESEARCH PROBLEM 
 
Assessing virus suppression using the viral load test and immunological recovery using 
the CD4 cell count are two objective strategies for adherence monitoring.  While CD4 
testing is generally being offered for initiating and monitoring treatment, the service is 
not easily accessible. Viral load testing is expensive and it is not currently offered 
routinely. It is therefore important to use objective, less expensive and easily accessible 
strategies such as pharmacy refills for measuring and monitoring ARV adherence. The 
level of ART adherence using pharmacy refills has not been investigated among HIV 
positive patients in Zimbabwe.   
 
1.4 AIM OF THE STUDY 
 
The aim of the study was to determine the level of adherence to ART when using 
pharmacy refills and the extent of the relationship between ART adherence when 
measured by pharmacy refills and immunological parameters of CD4 count and HIV-1 
RNA levels (viral load) among HIV positive patients at Mpilo Central Hospital, 
Zimbabwe.  
 
1.4.1 Study objectives  
 
The objectives of the study were to  
 
 describe the level of adherence to ART when measured by pharmacy refills 
compared to CD4 cell count and viral load  
 describe the relationship between adherence to ART when measured by 
pharmacy refills and CD4 cell count and viral load 
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1.5 SIGNIFICANCE OF THE STUDY 
 
The findings of the study have potential to contribute to the existing body of knowledge 
on ART adherence monitoring methods. Based on the findings of the study, pharmacy 
refills may be used routinely to monitor adherence to ART if found reliable when 
compared with CD4 count and viral load. It may  also be used as a screening tool for 
patients suspected of treatment failure to be referred for virological testing thus reduce 
the number of viral load tests done and inevitably the cost of providing this service.  
 
Health facilities with no access to CD4 testing or viral load testing and health facilities 
that are hard to reach or health facilities that currently have to wait for a long time for 
such results to be returned may better manage patients with available pharmacy refills 
data and not risk having patients lost to follow-up. At community level, information 
gained is important to help strengthen messages on prevention and or risk reduction for 
emergence of drug resistant HIV, reduction of community related barriers to adherence 
and promote community related facilitators to adherence.   
 
In addition, results from this study may provide baseline data on ART adherence levels 
and form a basis for prospective studies to be carried out to assess magnitude of non-
adherence and give more impetus for active HIV drug resistance monitoring in 
Zimbabwe. 
 
1.6 DEFINITION OF KEY WORDS AND CONCEPTS 
 
In order to ensure that specific meanings of words or concepts used in the study are 
understood in the context of this study, the following words and concepts are defined: 
 
1.6.1 Adherence  
 
According to the Pocket Oxford English Dictionary (2005), adherence means “to stick 
fast to substance, person, party, and opinion”. Adherence to treatment is defined as “the 
extent to which the patient continues the agreed-upon mode of treatment under limited 
supervision when faced with conflicting demands, as distinguished from compliance and 
maintenance (The Free Dictionary 2013a). For the purposes of this study, adherence 
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refers to the extent to which HIV positive patients’ behaviour of taking ART corresponds 
with agreed recommendations from a health care provider that ART is taken every day 
as prescribed and not missing any dose of ART.  
 
1.6.2 Antiretroviral therapy (ART) 
 
The antiretroviral drugs used as a combination of at least two different class drugs to 
suppress the HIV and stop the progression of HIV disease (Bean 2005:S96). ART was 
used in this study to refer to the drugs that the HIV positive patients are taking, 
prescribed in drug combinations referred to as highly active antiretroviral therapy 
(HAART) to suppress the HIV and stop the progression of HIV disease.  
 
1.6.3 HIV positive 
 
A person is said to be HIV-positive when antibodies against HIV have been detected on 
a blood test or gingival exudates test (commonly known as a saliva test). Synonym: 
seropositive (WHO 2011:79). The same definition will be used in this study.  
 
1.6.4 Measure 
 
According to Grove, Burns and Gray (2013:699), the “process of assigning numbers to 
objects, events or situations according to some rule” is known as measurement.  An HIV 
positive patient is prescribed ART as treatment for the rest of his or her life.  A patient 
on ART is required to visit a pharmacist at prescribed intervals to refill their 
prescriptions.  In this study the number of ART pharmacy refill visits (at prescribed 
intervals) that the patient makes, is used to measure adherence as defined above. 
 
1.6.5 Patients 
 
A sick individual under care and treatment or any recipient of health care services from 
health care providers or institutions is known as a patient (MedicineNet.com). In this 
study, persons seeking HIV and AIDS treatment and care at Mpilo Central Hospital will 
be defined as patients. 
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1.6.6 Pharmacy refills 
 
HIV disease is a chronic medical condition that requires treatment for the rest of the 
individual’s life. Usually a doctor prescribes ART to the individual that requires refilling 
(“usually a container which becomes empty through use”) (The Free Dictionary 2013b) 
by a pharmacists at prescribed intervals.  This definition will be used in this study. 
 
1.7 THEORETICAL FOUNDATION 
 
The paradigm and assumptions on which this study was founded are described in the 
paragraphs that follow 
 
1.7.1 Research paradigm 
 
A paradigm is defined as “a way of looking at natural phenomena…that encompasses a 
set of philosophical assumptions and that guides one’s approach to inquiry” (Polit & 
Beck 2012:736).  A paradigm plays an important role of directing research efforts and 
organising core ideas, theoretical framework and research methods. This study will be 
informed and guided by the positivist paradigm. Positivism is based on a belief in 
universal laws and an objective reality (Parahoo 2006:49). Positivists believe in the 
existence of a social and physical reality ‘out there’ that is driven by natural laws as well 
as the appropriate ways of going about finding knowledge (methodology). Its methods 
rely heavily on quantitative measures, with relationships among variables commonly 
shown by means of statistics. Researchers using positivism are concerned about facts, 
measurable behaviour as well as cause-and-effect.  
 
The strategies of inquiry used in quantitative research include experiments, surveys and 
predetermined instruments that yield statistical data (Creswell 2009:18). Parahoo 
(2006:50) explain that the quantitative paradigm adopts a deductive approach to 
research and the research process is objectively constructed and its findings are 
replicable and generalisable.  
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1.7.2 Assumptions of the study 
 
Assumptions refer to basic principles that are accepted as being true based on logic or 
reason without proof (Polit & Beck 2012:720), self-evident truths, statements or axioms, 
the truth of which are self-evident to those who hold them regardless of their objective 
status, meaning or truth value (Leedy & Ormrod 2005:5). Because all research is 
inevitably based on assumptions, it was important for the researcher to clarify 
assumptions to enable the readers to understand the basis on which the research was 
being conducted. The study was based on the following assumptions: 
 
 Adherence can be measured by patients’ pattern of antiretroviral drug collections 
as recorded in the pharmacy registers.  
 Adherence to ART can be predicted by virological suppression when measured 
by HIV-1 RNA levels.   
 Adherence to ART can be predicted by increment in CD4 cell counts if patients 
were consistent with their ARV drug refills.  
 Data was accurately recorded in the clinic registers where data for this study was 
extracted.    
 Majority of the patients use the same pharmacy for their refills. 
 
1.8 RESEARCH METHODOLOGY 
 
According to Coughlan, Cronin and Ryan (2007:661), the research methodology 
outlines the process involved or the “nuts and bolts of how a research study is 
undertaken. The research process undertaken in this study is discussed more in 
chapter 3 of this report.  Presented below is a brief outline of the research methodology 
followed. 
  
1.8.1 Study design 
 
The researcher used a non-experimental, quantitative, retrospective, descriptive and 
correlational design in order to achieve the objectives of this study.  Chapter 3 of this 
dissertation details the research design used.  
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1.8.2 Study setting 
 
The study was conducted at Mpilo Central Hospital a public health institution with an 
OI/ART clinic which was one of the Médecins Sans Frontières (MSF) Spain supported 
ART sites in Bulawayo city in Zimbabwe.  
 
1.8.3 Research methods  
 
The research methods used in the study included the population, sample and sampling 
procedures, data collection and data analysis. 
 
1.8.3.1 Study population 
 
The target population for this study was HIV positive adult patients initiated on ART 
between 1 October 2009 and 31 December 2009 and followed up for 12 months.  
 
1.8.3.2 Sampling procedure 
 
Probability sampling procedures were used to ensure that each element in the 
population had an equal and an independent chance of being selected and to achieve 
representativeness (Pilot & Beck 2012:275). Probability sampling is a technique used in 
quantitative research. All participant records that met the inclusion criteria were 
available to the researcher. The sample size of 118 was manageable and adequate for 
data analysis and as a result no sampling procedures were applied for this study.  
 
1.8.3.3 Data collection 
 
A data collection instrument was designed for this study (Annexure E) to collect data 
from the patients’ records.  Patient’s data was extracted from the facility health cards, 
clinic opportunistic infections (OI) registers and dispensing registers kept in the 
pharmacy onto the data collection instrument.  Each patient’s OI/ART number was 
recorded and the required information transcribed. 
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1.8.3.4 Data analysis 
 
Stata SE release 10 (STATA Corp, 2007) was used to analyse data. Details regarding 
the research methods used in this study are described in Chapter 3. 
 
1.9 ETHICAL CONSIDERATIONS 
 
The ethical protocols that were observed included permission to conduct the study from 
higher degrees committee of the University of South Africa and authorities of the 
research sites, anonymity and confidentiality as well as scientific integrity.  A full 
description of the stated ethical issues as well as the measures taken to address each 
of the issues is discussed in chapter 3.  
 
1.10 OUTLINE OF THE STUDY DISSERTATION 
 
The study report for this research is divided into chapters outlined below: 
 
Chapter 1: Orientation and overview of the research study. 
Chapter 2: Literature review on adherence to ART.  
Chapter 3: Research methodology 
Chapter 4: Presentation and analysis of the study findings. 
Chapter 5:  Conclusions and recommendations. 
 
1.11 CONCLUSION 
 
This chapter provided an orientation to the study. The background information about 
the research problem, aim and objectives of the study, the study design, methods and 
ethical issues were introduced. Terms used in the study were defined, the significance 
of the study and ethical consideration were discussed.  Lastly, an outline of the 
structure of the chapters of the dissertation was presented. In the next chapter, the 
literature review pertinent to the adherence to ART is presented 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1 INTRODUCTION 
 
In this chapter, the findings of a review of literature pertaining to ART adherence are 
presented. The purpose of the literature review was to familiarise and widen the 
researcher’s knowledge base of trends and developments in the field of study of HIV 
and AIDS and ART adherence. By reviewing literature, the researcher was able to 
identify what is already known about ART adherence and knowledge gaps in literature. 
Literature reviews give the researcher impetus for conducting the study and help avoid 
unintentional duplication (Grove et al 2013:40). According to Grove et al (2013:98-99), 
when literature review for a study that is quantitative in design is done, the process is 
aimed at directing the development and implementation of the study and ultimately 
producing a written report thereby adding to the body of knowledge for the research 
area.  
 
2.2 SCOPE OF THE LITERATURE REVIEW  
 
A computer-assisted search was conducted using the keywords: HIV and AIDS 
treatment, adherence to ART and measuring adherence.The reviewed literature 
comprised various reports and research conducted on HIV/AIDS and ART adherence 
globally including the country of the study, Zimbabwe.  Literature reviewed for this study 
was for the period between 2000 and 2013 
 
2.3 HIV AND AIDS  
 
The reviewed literature on HIV and AIDS is presented using the headings HIV and AIDS 
epidemic, HIV and AIDS disease. 
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2.3.1 HIV and AIDS epidemic 
 
Three decades ago, Human Immunodeficiency Virus (HIV), was identified as the cause 
of Acquired Immune Deficiency Syndrome (AIDS). The predominant virus type that 
causes the highest HIV disease burden worldwide is HIV-1.  In 2010, an estimated 34 
million people were living with HIV globally, 2.7 million got newly infected and 1.8 million 
died (WHO 2011:11, 49).  Global initiatives to tackle the epidemic have been strong, 
with multi prong approaches including prevention, care, support and treatment (WHO 
2011:3) as well as health systems strengthening programmes (WHO 2011:4); all 
mutually reinforcing strategies for an effective response. The impact of these initiatives 
has been significant.  There are indications that globally both HIV incidence and 
prevalence have declined (WHO 2011:13-18). Most encouraging, worldwide over 6.6 
million HIV infected people were receiving antiretroviral therapy by end of 2010 (WHO 
2011:97).   
 
The vast majority of the HIV and AIDS epidemic is in sub-Saharan Africa.  In 2010, an 
estimated 68% of all people living with HIV and AIDS were from sub-Saharan Africa 
(WHO 2011:24). By the end of 2009, sub-Saharan Africa was home to 22.5 million of 
the 33.3 million people living with HIV and AIDS worldwide (UNAIDS 2010:20) with an 
estimated 10.4 million in sub-Saharan Africa in need of treatment (WHO 2011:97). In 
the sub-Saharan region, women are disproportionately affected; accounting for 59% of 
the HIV infected population (WHO 2011:19).  For sub-Saharan Africa, UNAIDS 
estimates that 1.9 million people were newly infected with HIV and 1.2 million died in 
2010 (WHO 2011:10, 13, 25). Despite carrying the biggest burden of the HIV disease, 
slightly over 5 million people in sub-Sahara Africa were receiving ART by end of 2010, 
representing 49% of the total HIV infected persons on ART in low – and middle-income 
countries and a 30% increase in coverage from December 2009 (WHO 2011:97).  
 
Zimbabwe is among the countries with the world’s highest HIV infection rate with 
heterosexual contact being the main mode of transmission (WHO 2011:25, 26, 30). 
According to the Ministry of Health and Child Welfare (MOHCW) estimates, 14.3% of 
the adult population between 15-49 years were infected with HIV in 2009 (Joint United 
Nations Programme on HIV/AIDS (UNAIDS) Report on the Global AIDS epidemic 
2010:181). Children account for 7% of people living with HIV and AIDS (PLWHA) in 
Zimbabwe making mother to child transmission (MTCT) an important mode of 
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transmission of HIV in Zimbabwe (USAID 2003:10).  Over 90% of the HIV infections are 
due to heterosexual sexual contact (USAID 2003:10).  According to WHO, Zimbabwe is 
among a few countries in the sub-Sahara Africa which has realised significant declines 
in prevalence in recent years (WHO 2011:24).  In Zimbabwe, the HIV epidemic peaked 
in the mid-to-late 1990’s with HIV prevalence among Antenatal Care (ANC) mothers 
exceeding 30% and 25% among adults 15-49 years (UNGASS 2010:11-12).  HIV 
prevalence in 2009 was14.3%, marking a significant drop from the previous years 
(UNGASS 2010:10) and the rate has generally remained low even though there has 
been an observed increase to the latest prevalence rate of 15% for the year 2013 
(UNAIDS 2014:4). Overall much of the decline in prevalence has been attributed to 
behavioural change and to ART, which is increasingly becoming more available 
(UNAIDS 2010:28).  
 
2.3.2 HIV and AIDS disease  
 
The virus that causes Acquired Immune Deficiency Syndrome (AIDS) is called the 
Human Immunodeficiency Virus (HIV).  The virus infects the human body by integrating 
its viral genetic material deoxyribonucleic acid (DNA) into human cells called CD4+ T 
cells and redirects or takes over their purpose and normal function of fighting infections, 
to producing more of the virus. In clinical settings, HIV infection can be detected by 
measuring HIV antibodies produced against the virus.  HIV antibodies can be detected 
in the blood approximately 3 weeks after HIV infection and can be detected throughout 
the individual’s life (Cohen, Gay, Busch & Hecht 2010:S271-S272).    
 
Prior to HIV antibodies being detected in the blood, HIV infection can also be detected 
in the blood by measuring presence of the virus itself, HIV RNA (virions) or viral load 
and HIV DNA using  molecular techniques called polymerase chain reaction (PCR).  
HIV DNA PCR is generally used as a qualitative test for HIV infection and often used in 
public health HIV and AIDS programmes to diagnose HIV infection mostly in children 
less than 18 months. In more sophisticated methods, PCR can also be used to quantify 
how much proviral HIV DNA is integrated into the CD4+ T cells. This is increasingly 
becoming an important parameter to assess, since some CD4+ T cells (known as 
resting CD4+ T cells) may be infected (proviral DNA) and will lie dormant not replicating 
or producing HIV, but ready to go into viral replication if triggered (Cummins & Badley 
2010:2; Sedaghat, Siliciano, Brennan, Wilke & Siliciano 2007: 1165). This form of virus 
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is important when considering ART treatment and the importance of adherence as the 
virus can emerge if ART is stopped or fails (Sedaghat et al 2007:1165-1166). 
 
2.3.2.1 Staging of HIV disease 
 
The CD4+ T cell counts in healthy persons range from 500-1000 cells/mm3 and above 
(Alimonti, Ball, & Fowke 2003:1650; Mocroft, Phllips, Gatell, Ledergerber, Fisher, 
Clumeck, Losso, Lazzarin, Fatkenheuer & Lundgren 2007:411).  As the virus replicates, 
more and more of the CD4+ T cells get destroyed and decrease in number and function 
and the viral load increases (Alimonti et al 2003:1650-1654). Without treatment, the 
individual’s immune system gets compromised and more prone to other infections 
known as opportunistic infections (OIs) (Alimonti et al 2003:1650, Cummins & Badley 
2010:1), leading to AIDS which is the end stage of the HIV disease (Cummins & Badley 
2010:2).  Peripheral blood CD4+ T cell count and viral load measurements are thus 
valuable tools for staging HIV disease and facilitate in the identification of patients 
eligible for ART initiation.  These assays are also used as surrogate measures of 
adherence and in detecting treatment failure (especially with viral load). In the absence 
of CD4 cell count and viral load testing, The WHO has established a set of clinical 
guidelines based on clinical manifestations that help in the determination of eligibility for 
treatment and management of HIV patients. The stages are divided into four, with each 
stage having specified clinical conditions and or symptoms used in assessing HIV 
disease progression (National Drug &Therapeutics Policy Advisory Committee 
(NDTPAC) & AIDS and TB Unit MOHCW 2010:62).  The four stages are as follows: 
 
 Clinical Stage 1 - patient is asymptomatic.  Patients may present with persistent 
generalised lymphadenopathy but are generally well. ART initiation is 
recommended if CD4 cell count is ≤350 cell/mm3 (WHO 2010c:21, 30, 73). 
 
 Clinical Stage 2 – patients in this stage are considered to present with mild 
manifestations of the opportunistic infections and HIV defining illnesses indicative 
of HIV progression.  Manifestations involved include but are not limited to Herpes 
zoster, moderate unexplained weight loss, papular pruritic eruptions, recurrent 
bacterial and fungal infections among others.  ART initiation is recommended if 
CD4 cell count is ≤350 cell/mm3 (WHO 2010c:21, 29, 73). 
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 Clinical Stage 3 – patients in this stage are described as being in an advanced 
stage of the HIV illness.  Patients present with severe unexplained weight loss, 
chronic diarrhoea, oral candidiasis, severe bacterial infections, oral hairy 
leukoplakia, unexplained fever, unexplained anaemia, acute necrotising 
ulcerative stomatitis, gingivitis or periodontitis and pulmonary TB.  ART initiation 
is recommended irrespective of CD4 cell count (WHO 2010b:52, WHO 2010c:21, 
29, 74-76). 
 
 Clinical Stage 4 – this is considered the severe clinical stage of the HIV illness 
with a whole host of opportunistic infections of bacterial, fungal and parasitic 
origin presenting.  There are considerable manifestations of tumours (e.g. Kaposi 
sarcoma) and involvement of organ pathologies such as those of the kidneys and 
heart. ART initiation is recommended irrespective of CD4 cell count (WHO 
2010b:52, WHO 2010c:21, 29, 76-80). 
 
2.3.2.2 Antiretroviral treatment 
 
Antiretroviral drugs are treatment drugs aimed at fighting HIV infections. They do not 
cure or get rid of the HIV infections, but retard or prevent the virus from replicating 
allowing the immune system to gain control and preventing opportunistic infections from 
causing AIDS.  HIV has a high replication and mutation rate and it has been shown that 
when the ARVs are not taken correctly or if doses are missed, the therapeutic levels 
required to retard or prevent viral replication are compromised (Harrigan, Hogg, Dong, 
Yip, Wynhoven, Woodward, Brumme, Brumme, Mo, Alexander & Montaner 2005:339).  
If the drug therapeutic levels are low, HIV is able to replicate in the presence of the 
antiretroviral drugs thereby creating an environment conducive for the development of 
drug resistance (Harrigan et al 2005:342; Peltzer et al 2010:1). The main aim of 
antiretroviral drugs is to control the rate at which the virus reproduces thereby reduce 
viral load (Deeks 2003:2002), allow restoration of CD4 cell count (Lucas 2005:413) 
resulting in prevention or delayed progressive immunodeficiency, reduced morbidity and 
mortality (Bisson, Gross, Bellamy, Chittams, Hislop, Regensberg, Frank, Maartens & 
Nachega 2008a:0778; Nachega 2011:209) delay progression to AIDS resulting in 
prolonged survival and improved quality of life (Bean 2005:S96; Bisson et al 
2008a:0778; Nachega 2006:81-83). Equally important ARVs reduce selection of 
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resistant virus (Bean 2005:S96; Deeks 2003:2002; Fergusson 2005:349; Lucas 
2005:413- 414; Harrigan et al 2005:339).  When antiretroviral drugs are taken according 
to prescribed regimes, virus loads in blood can become undetectable, although not 
eliminated, making HIV disease a condition that is now manageable but not curable 
(Bean 2005:S96; Lucas 2005:413; Martin et al 2008:1263). For that reason, managing 
HIV disease requires a comprehensive multi-prong approach which includes counselling 
and testing as an entry point to care, prevention and treatment including opportunist 
infections and proper nutrition in order to control its spread (WHO 2011:24).   
 
2.3.2.2.1 Importance of HIV-1 life cycle in treatment strategies 
 
HIV-1 is a Ribonucleic acid (RNA) retrovirus belonging to the lentivirus family, also 
characterized as slow viruses. Because retroviruses have RNA and no deoxyribonucleic 
acid (DNA) as their genetic material, they can only replicate if they have a host cell. The 
retrovirus HIV infects human immune T cells that have a CD4 receptor (CD4 + T cells). 
These CD4+ T cells have cell surface receptors, which have high affinity for HIV to 
attach to and thus gain entry into the cell (Borkow & Lapidot 2005:4-6). Chemokine co-
receptors CCR5 and CXCR4 mainly found on non CD4 + T cells such as macrophages 
and dendritic cells are central in facilitating HIV infection through these cells (Borkow & 
Lapidot 2005:4). A unique feature to retroviruses is that they replicate backwards. HIV, 
using an enzyme called reverse transcriptase replicate by going from RNA to single 
stranded DNA (ssDNA) to double stranded DNA (dsDNA) (Borkow & Lapidot 2005:3).  
The virus then uses another enzyme called integrase to insert the viral DNA into the 
host cell nucleus to become what is known as HIV proviral DNA. Once inside, the virus 
takes over the host cell’s genetic code and diverts the cell’s normal function of 
defending the body from infections to production of HIV (RNA) virions. For this function 
the virus uses another enzyme called protease. Virions are released from the CD4+ T 
cell by budding off from the cell surface or as a result of the CD4+ T cell dying 
(Cummins & Badley 2010:7). The released virions in turn infect more CD4+ T cells 
resulting in more and more infected cells producing increasingly more HIV copies. 
Although the human immune system responds appropriately by producing antibodies 
against HIV, these are not protective. HIV has a very high rate of replication, making it 
also very prone to replication errors that can give rise to new HIV strains due to 
mutations (Bean 2005:S96; Deeks 2003:2002). The implications are in part that very 
high, greater than 95% adherence levels are needed to suppress and sustain virus 
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suppression (Paterson, Swindells, Mohr, Brester, Vergis, Squier, Wagener & Singh 
2000:24-28) and antiretroviral drugs have thus far been produced to target different 
stages of the replication cycle (Bean 2005:S96-S100; Borkow & Lapidot 2005:3-8; 
Emmelkamp & Rockstroh 2007:36-39).  
 
Figure 2.1   HIV-1 Replication cycle 
(Google Images 2014) 
 
2.3.2.2.2 Classes of antiretroviral drugs for HIV infection used in Zimbabwe 
  
ARV drugs are grouped according to how they function, specifically how they interfere 
with the replication processor cycle focusing at critical replication stages or factors 
(Bean 2005:S96-S100; Emmelkamp & Rockstroh 2007:36-39; Wood R 2005: 9-51). The 
following are some of the classes of ARVs: 
 
 Nucleotide and nucleoside reverse transcriptase inhibitors (NRTIs) − first 
approved to treat HIV in 1987(AVERT 2012; Emmelkamp & Rockstroh 2007:36). 
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Examples of those in use in Zimbabwe ART programme include Tenofovir, 
Zidovudine, Lamivudine, Stavudine, Abacavir, Emtricitabine and didanosine. 
These ARVs interfere with the reverse transcriptase enzyme’s function of 
transcribing viral RNA into proviral DNA (Bean 2005:S96; NDTPAC & AIDS and 
TB Unit MOHCW 2010:11-12).  
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) − first approved to treat 
HIV in 1997 (AVERT 2012). These ARVs inhibit the enzyme reverse 
transcriptase needed in the replication process as earlier indicated, however with 
some differences in the mode of action (Bean 2005:S97-S98) which essentially 
results in the blockage of both RNA and DNA dependent DNA polymerase 
functions.  Examples and those in use in Zimbabwe are Nevirapine, 
Efavirenz,and Etravarine (NDTPAC & AIDS and TB Unit MOHCW 2010:11-12). 
 Protease inhibitors (PIs) – first approved to treat HIV in 1995 (AVERT 2012). 
These drugs inhibit the assembly and maturation stages of the replication cycle 
by the enzyme protease. Infectious virons are not released into the system 
thereby limiting further re-infection of CD4+ T cells (Bean 2005: S98). In 
Zimbabwe examples of approved PIs for use include Lopinavir, Ritonavir, 
Atazanavir, Indinavir Darunavir and Saquinavir (NDTPAC & AIDS and TB Unit 
MOHCW 2010:12).  Current treatment strategies for Zimbabwe have limited use 
of these drugs to second line regimes (NDTPAC & AIDS and TB Unit MOHCW 
2010:11-12).  
 Fusion inhibitors (FIs) or entry inhibitors first approved to treat HIV in 2003 
(AVERT 2012) are ARVs, which interfere with the virus’s ability to attach to CD4+ 
T cells.  Example is Enfuvirtide.  Fusion inhibitors are not yet included in the 
Zimbabwe national ART regimes (NDTPAC & AIDS and TB Unit MOHCW 
2010:12). 
 Integrase inhibitors − first approved to treat HIV in 2007 (AVERT 2012). Example 
is Raltegravir.  These are not yet in use in the Zimbabwe national ART 
programme (NDTPAC & AIDS and TB Unit MOHCW 2010:12). 
 Chemokine co-receptor antagonist (CCR5 or CXCR4 receptor inhibitors).  
Maraviroc is one example that blocks the receptor that HIV uses to gain entry 
into CD4+ T cells. These are also not yet in use in Zimbabwe (Emmelkamp & 
Rockstroh 2007:38-39; NDTPAC & AIDS and TB Unit MOHCW 2010:12). 
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2.3.3 Treatment protocol for HIV infection 
 
Standard treatment protocols for HIV infection require the combination of at least three 
or more ARV drugs or Highly Active Antiretroviral Therapy (HAART)  in order to 
decrease selection of resistant virus (Bean 2005:S96; Lucas 2005:413-414). Whilst 
monotherapy has been used in the past for the prevention of mother to child HIV 
transmission for pregnant women around delivery, use of one drug is no longer 
recommended due to the rapid development of drug resistance and treatment failure 
(Borkow & Lapidot 2005:3, Deeks 2003:2002; Lucas 2005:413). 
 
In Zimbabwe triple therapy is recommended. Suppression of HIV replication and 
prevention of HIV drug resistance are the short to medium term goals of antiretroviral 
therapy adherence. Prevention or delayed progression of immune deficiency to AIDS 
and prolonged survival are the long-term goals of ART adherence (Deeks 2006:1489-
1490, Lucas 2005:413). The national ART guidelines for Zimbabwe recommend usage 
of two NRTIs and one NNRTI as first-line ART drug regimens for adults and 
adolescents (NDTPAC & AIDS and TB Unit  MOHCW 2010:22-25). Protease inhibitors 
(PIs) are currently used in second-line ART drug regimens together with two NRTIs 
(NDTPAC & AIDS and TB Unit MOHCW 2010:25). According to the national ART 
guidelines, adult and adolescent patients are initiated on ART under the following 
conditions:  
 
 WHO stage III or IV disease (irrespective of CD4 cell count for pregnant women). 
 HIV positive with CD4 cell count ≤350 cells/mm3 regardless of WHO staging. 
 HIV positive with active tuberculosis (TB) irrespective of CD4 count for pregnant 
women (NDTPAC & AIDS and TB Unit MOHCW 2010: 14-15, 30).   
 
According to the national ART guidelines, adolescents are defined as persons aged 
between 10 and 18 years and emphasises the requirement for persons in this age 
group to be weighed before ART initiation so that patients weighing less than 25 
kilograms can be initiated using paediatric guidelines (NDTPAC & AIDS and TB Unit 
MOHCW 2010:17). In pregnant women, WHO (2010) guidelines are used to assess 
whether a woman needs treatment prophylactically for prevention of HIV transmission to 
the unborn baby or treatment for her own health (WHO 2010a:2-12). According to this 
guidance, HIV positive pregnant women with CD4 cell count less than 350 not only 
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need treatment to prevent transmission to the unborn baby, but need treatment for their 
own health.  On the other hand, women with CD4 cell counts higher than 350, are 
initiated on prophylactic ARVs primarily to prevent transmission of HIV to the unborn 
baby (WHO 2010a:2).  
 
The National ART guidelines (NDTPAC & AIDS and TB Unit MOHCW 2007:16) also 
emphasize that starting ART should not be an emergency and thus acknowledges and 
requires adequate preparation of patients before initiating ART. The initiation protocol 
therefore requires the patient to undergo counselling sessions including adherence 
counselling prior to ARVs being dispensed. A month’s supply of drugs is given to the 
patient and an appointment for the next pharmacy refill is given. At every subsequent 
pharmacy refill, the pharmacist or health care provider dispensing the ARVs is expected 
to review and assess adherence by using pill counts and possibly adherence cards if 
patient was issued one (NDTPAC & AIDS and TB Unit MOHCW 2007:24-25). 
 
2.4 HIV AND AIDS PROGRAMMES IN ZIMBABWE 
 
Implementation of HIV and AIDS programmes in Zimbabwe on prevention, care and 
treatment, support and mitigation are coordinated by the AIDS and TB Unit.  The AIDS 
and TB Unit  was set up by the government of Zimbabwe through the MOHCW in 2000 
as a successor to the National AIDS Control Programme (NACP) which was set up in 
1992 (AVERT 2011, USAID 2003:11).  Prevention of Mother to Child Transmission of 
HIV (PMTCT), Care and Treatment (includes opportunist infections (OI) and 
antiretroviral therapy (ART) programmes), HIV testing and counselling, condom 
programmes and workplace prevention programmes are among the Unit’s core 
implementation programmes. At national level ARV drugs in Zimbabwe have mainly 
been provided through the PMTCT and OI/ART programmes. 
 
2.4.1 PMTCT programme in Zimbabwe 
 
Introduced in 1999 as a pilot project in three sites, the PMTCT programme became a 
national programme in 2001.  The goal of this programme is to provide comprehensive 
PMTCT services and prevent infant mortality and morbidity. Treatment strategies for 
this programme when first implemented focused mainly on HIV positive mothers 
receiving single dose nevirapine (SdNVP) at the onset of labour and nevirapine syrup to 
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their exposed babies immediately postpartum. This was seen as a simple, effective and 
easy strategy to implement especially for resource poor settings (MOHCW Trainer’s 
Manual Module 9 2008:1; AVERT 2011).  Revised August 2006, WHO PMTCT 
guidelines encouraged programmes to move away from single dose NVP to More 
Efficacious Regimen (MER), starting antenatally (28 weeks), during labour and 
postnatal prophylactic ARVs to the exposed infant (WHO 2006:27-32).  The 
recommendation was based on studies that showed a reduction in the number of new 
infections in infants and young children and also reduced risk of HIV resistance (WHO 
2006:28-32). Only a limited number of sites were able to implement this strategy owing 
to lack of resources resulting in Zimbabwe reporting close to 80% SdNVP use by end of 
2009, about 15% combined ARVs and less than 5% ART among HIV positive pregnant 
women (Wilfert 2010:23).  
 
Current PMTCT guidelines issued in 2010 by the WHO, recommends earlier initiation of 
prophylactic ARVs during pregnancy, initiation of ART for pregnant women in need for 
treatment for their own health and prolonged prophylactic ARVs for the HIV exposed 
infants postnatally to prevent HIV transmission during the breastfeeding period (WHO 
2010a:3-9). It is estimated that with the current PMTCT ARV treatment strategy, MTCT 
can be reduced to less than 5% among breastfeeding populations and to less than 2% 
in non-breastfeeding populations (WHO 2010a:12). Central to the effectiveness and 
efficacy of all these ARV treatment strategies is adherence and ultimately prevention of 
preventable HIV drug resistance (WHO 2010a:34).  Adherence studies in Zimbabwe 
among women and or children initiated on these different ARV treatment strategies over 
the years is scarce. 
 
2.4.2 ART programme in Zimbabwe 
 
The national ART programme in Zimbabwe started in 2003 and since then HIV positive 
patients have been receiving ARVs free of charge. When the programme was started, 
the National AIDS Council (NAC) through funds collected by a tax levy instituted by the 
Government of Zimbabwe channelled 50% of the funds to purchasing of ARV drugs 
(UNGASS 2010:14).  However, when the country was undergoing economic hardships 
mid to late 2000, which saw world record inflation rates being recorded, value from 
these proceeds dwindled (AVERT 2011; UNGASS 2010:14). Leverage funds from 
international agencies such as the Global Fund for AIDS, Tuberculosis and Malaria 
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(GFATM), United Kingdom Department for International Development (DFID), United 
States International Development (USAID), United Nation agencies, Expanded Support 
Programme (ESP) and others ensured continuation of the ART programme (AVERT 
2011; UNGASS 2010:14).  
 
Initially, implementation of the ART programme was limited to Government central 
hospitals with decentralisation to district and some mission hospitals thereafter 
(MOHCW 2004:4). By December 2010, an estimated 326,241 (59%) HIV positive 
people were receiving ART through the National ART program, up from 218,589 the 
preceding year (WHO 2011:98).  Between this period Zimbabwe recorded the highest 
percentage increase in coverage of 49%. Whilst these indicators were impressive, they 
still fell far below the expected 80% of the population that were in need of ART (WHO 
2011:90). During the same period, the WHO HIV/AIDS clinical staging instead of CD4 
count was the main criteria used for ART initiation (MOHCW 2008:12; NDTPAC & AIDS 
and TB Unit  MOHCW 2007:10) due to lack of laboratory support ranging from shortage 
of qualified laboratory staff, equipment (and equipment breakdown), reagents and 
consumables (AVERT 2011; MOHCW 2008:12). Facilities where CD4 testing capacity 
can be accessed, user fees for other services rendered by the health facility and the 
long distances that patients have to travel to access ART services have also hampered 
equitable access to these HIV and AIDS services in Zimbabwe (AVERT 2011). During 
the peak of economic decline that Zimbabwe experienced mid to late 2000, there were 
reports of bribery by patients to access ARVs and patients migrating to neighbouring 
countries such as South Africa and Botswana to access ARVs (AVERT 2011).  
 
The National ART programme has a monitoring and evaluation system in place. The 
current system is mostly paper based including patient hand held OI/ART cards and 
health facility registers including pharmacy ART dispensing registers.  An OI/ART 
electronic database is still under development (MOHCW 2008:8). 
 
Over the years, the MOHCW of Zimbabwe has implemented the OI/ART treatment 
programme along with other HIV preventative programmes as part of a comprehensive 
approach to combat the disease (WHO 2011:62).  Overall treatment strategies are 
geared at rapidly suppressing viral replication thereby reducing viral load in the blood. 
Central to achieving this goal is adherence – how to maximise and sustain high 
adherence to ARVs once initiated. 
 
23 
 
2.5 ADHERENCE TO ART 
 
In health the term adherence is often used to describe a patient’s consistent behaviour 
around taking medication. The World Health Organization (WHO) defines adherence as 
the extent to which an individual’s behaviour with regards to taking medications 
changes in accordance to recommendations by the health care provider (WHO 2003:3). 
According to WHO, the behaviour and lifestyle modifications important for successful 
treatment outcomes require “good communication between patient and health 
professional” and include negotiations, plans and discussions around how best to go 
about consistent taking of medication that ensures good adherence (WHO 2003:4).  
Central to adherence is the ability of the ART programme to make sure that the service 
is easily accessible and drug supplies are not interrupted once introduced.  In addition 
adherence to ART requires the patient to take the correct dosage of prescribed drugs at 
the stipulated times and sticking to dietary restrictions (Peltzer et al 2010:1).  
 
A systematic review of adherence studies that included 27 African studies (total 12,116 
patients) and 31 studies in North America (total 17,573 patients) assessed adherence 
levels in these diverse settings and provided evidence of even higher adherence levels 
in resource poor settings when compared to the developed settings (Mills et al 2006b: 
682). In that meta-analysis, significantly higher adherence levels (p<.001) were 
observed when comparing adherence to antiretroviral therapy between North American 
and African patients, with a pooled adherence estimate of 54.7% (95% CI: 48.0-61.3%) 
in North America compared to 77.1% (95% CI: 67.3- 85.6%) in Africa (Mills et al 
2006b:682). 
 
In another study, adherence was assessed in a cohort of 99 patients receiving 
antiretroviral therapy with a protease inhibitor seen in two different HIV clinics in the 
United States of America (USA) (Paterson et al 2000:22). In that study, adherence 
levels measured with MEMS in 81 patients were compared to both outcomes of virology 
(virologic failure defined by a viral load greater than 400 copies/mL on the last study 
visit) and clinical (defined by the changes in CD4 counts measured at baseline and at 
the last study visit – that is the difference or CD4 gain or no gain). Virologic failure at the 
final study visit among patients with baseline viral load of 400 copies/mL or greater was 
significantly associated with degree of adherence with 31% (5/16) of the patients with 
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95% or higher adherence levels having detectable viral load, compared to 85% (35/41) 
for patients with adherence levels less than 95% (Paterson et al 2000:25). For clinical 
outcomes assessed with CD4 count, patients with adherence level of 95% or greater 
had mean increase of 83 cells/mm3 compared to 6-cells/mm3 mean increases among 
patients with less that 95% adherence (Paterson et al 2000:25). Opportunistic infections 
were only observed in patients with less than 95% adherence (3/58), further supporting 
and emphasising the importance of near perfect adherence required among HIV 
patients. This study benchmarked the degree of adherence for HIV treatment, 95% or 
greater which has been used in many studies on HIV ART adherence and general 
clinical practice have used this benchmark to define adherent and non-adherent 
patients.   
 
2.5.1 Relationship between adherence and treatment outcomes 
 
Whilst there is no consensus on what adequate adherence is, researchers are in 
agreement that successful ART treatment demands high adherence and National HIV 
treatment programmes need to focus on adherence strategies in order to preserve the 
effectiveness of first line therapy through sustained high levels of adherence (Bisson et 
al 2008a:0786). Treatment outcomes for individuals depend highly on ability to adhere 
and maintain high enough drug levels to retard viral replication and allow for 
immunological recovery.  
 
The public health consequences of failure to adhere to ART are grave due to the 
potential emergence of cross-resistance (Deeks 2003:2003) where HIV becomes 
resistant to similar drug formulations and risk of the emergence and transmission of 
drug resistant HIV (Deeks 2003:2002-2003) leading to reduced treatment options 
available at population level (Deeks 2003:2002).   
 
Ninety-five (95%) adherence level is considered the minimum requirement for HIV 
treatment success. There is evidence that not as high adherence levels can equally 
achieve viral suppression due to the composition of the ARVs the patient is initiated on. 
A study among HIV positive adults in South Africa, Nachega et al (2007:564-573) used 
pharmacy claims to study the relationship between adherence and virologic outcome for 
a cohort of 2821 patients initiated on Nonnucleoside reverse transcriptase inhibitor 
(NNRTI) based ART between January 1998 and March 2003.   The viral load for 
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patients studied was greater than 400 copies/mL at initiation. Individual patient 
adherence levels were calculated and categorised into seven categories of 10% 
increments ranging from less than 50% to 100% (Nachega 2007: 565). The primary 
outcome of the study was the proportion of patients achieving viral suppression (less 
than 400 copies/mL HIV-1 RNA) from one month after ART initiation till end of follow-up 
(median 2.2 years), or till death or withdrawal (Nachega 2007:565-566).  Pharmacy 
claims were used for measuring adherence. A linear dose response relationship 
between viral load suppression and adherence was observed and viral suppression 
rates of greater than 70% was significantly associated with patients with pharmacy 
claim rates of 80% or more (Nachega 2007:566-567). In multivariate analyses, higher 
pharmacy claim adherence was statistically and significantly associated with shorter 
time to viral suppression with a hazard ratio of 3.79 [CI; 3.13- 4.58] when comparing 
patients with 100% to those with 50% or less adherence levels (Nachega 2007:567). In 
this study with NNRTI based ART, favourable incremental virologic outcomes were 
observed in patients with 50% or greater adherence levels (Nachega 2007:568) with the 
authors concluding that with such a regimen for HIV-1 treatment, greater than 70% 
adherence maybe sufficient for sustained viral suppression.   
 
In a similar study, a prospective cohort study of 1142 patients in Barcelona used 
announced pill counts and pharmacy claims to study the relationship between 
adherence level, ARV regime and viral suppression (Martin et al 2008:1263-1264). Of 
the 1142 patients, 662 (58%) were on NNRTI based regime, 359 (31.4%) PI boosted 
regime and 121 (10.6%) were on unboosted PI regime. Patients with undetectable viral 
load (n=1059) had a mean adherence of 95.7% compared to 76.3% (n=86) for those 
patients with detectable viral load. Looking at the relationship between virologic failure 
and adherence; patients with adherence between 80-89.9% had a 9.0 relative risk (RR) 
(95% CI 4.0-20.1) of virologic failure, 45.6 RR (95% CI 19.9-104.5) for patients with 
70.0-79.9% adherence and finally 77.3 RR (95% CI 34.2-174.9) for patients with 
adherence less than 70% (Martin et al 2008:1265). The relationship between adherence 
and virologic failure in patients taking different ARV regimes showed that the relative 
risk of virologic failure was 26.6 (95% CI 3.0-230.7) for patients on unboosted PI 
regimes with adherence between 80-89.9%, 207.5 RR (95% CI 16.0-2696.2) for 
adherence between 70-79.9% when compared to patients with adherence of 90% or 
greater. For patients taking boosted PIs, similar trends were observed for relative risk of 
virologic failure being 21.5 for patients with adherence between 80-89.9%, RR of 124.7 
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for patients with adherence between 70-79.9% and RR of 212.0 for patients with less 
than 70% adherence compared to those with adherence of 90% or greater. In NNRTI 
based patients, RR of 4.4 (95% CI 1.4-13.3) for patients with adherence between 80-
89.9%, 22,4 (95% CI 7.5-66.8) in patients with adherence between 70-79.9% and 36.9 
(95% CI 12.7-107.5) for patients with adherence less than 70% when compared to 
those with 90% or greater. Compared to the other two ARV regimes, the 95% CI for 
NNRTIs were much tighter even though statistically there was no difference in relative 
risk of virologic failure for patients taking PI-boosted ARVs and NNRTIs.  Logistic 
regression analysis, did however show a 2.5 higher relative risk of virologic failure in 
patients with <90% adherence and taking unboosted PIs, compared to patients taking 
boosted PIs (95% CI 1.179-5.341). Overall the ARV regime class predicted adherence, 
with NNRTI based patients having an overall adherence of 96.2% (CI 90-100) 
compared to 92.6% (CI 84.6-97.9) for those patients on PI based ARVs (Martin et al 
2008:1265). These studies are in agreement with others which have shown similar 
“more forgiving” adherence requirements (Shuter 2008:769-773), clearly suggesting the 
possible different adherence levels required depending on the composition of the ARV 
regime, and in general also highlighting the complexity of HIV treatment which includes 
pharmacological, viral and host factors. Irrespective of what is considered adequate 
adherence; overall, different studies have pointed to the fact that adherence needs to be 
promoted for ART to be successful, with the ultimate goal of achieving 100% adherence 
promoted and recommended for every patient initiated on ART (Martin et al 2008:1267). 
 
2.5.2 Adherence to ART and HIV drug resistance 
 
HIV drug resistance is a major cause of concern in treatment programmes and an 
important reason why non-adherence, which includes among others not taking the 
correct dose, missing doses or not taking medications at prescribed time intervals 
should be discouraged. As discussed, antiviral drugs for HIV have been developed 
mainly to interrupt the replication cycle of the virus. Because of its very high rate of 
replication which is also prone to mistakes (Deeks 2003:2002), giving rise to mutations 
and generational viral differences (Deeks 2003:2002) maintaining high to near perfect 
adherence levels is a critical factor to successful and sustained interruption of the 
replication cycle.  When drug levels fall below therapeutic levels or levels not high 
enough to inhibit the virus from replicating, the virus can continue to replicate in this 
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environment and ultimately lead to the development of viral strains that are not easily 
controlled by treatment and become resistant to ARVs.  Drug resistant HIV can cause 
treatment to fail, viral load to increase and can limit the choice of drugs available for 
treatment (Lucas 2005:413). Even more concerning is that drug resistant viruses can be 
transmitted with the potential of becoming the dominant HIV strain in a population 
(Deeks 2003:2002-2003; Veenstra 2010:1; Vervoort et al 2007:271) requiring more 
resources not only to understand it but also to combat it. Another problem closely linked 
with drug resistance and adherence is cross-resistance. This phenomenon occurs when 
HIV resistant to a particular ARV drug, also becomes resistant to other ARV drugs in the 
same class as the primary (failing) drug causing resistance (Lucas 2005:413). The main 
problem presented with this situation, especially in resource constrained settings; is the 
limited choice of ARV drugs available to replace the failing drug and the need for more 
complex treatment regimens which are not readily available due to high costs.     
 
2.5.3 Factors that influence adherence 
 
There are several factors that can influence how well or how badly an individual 
adheres to ART. According to WHO, factors that can affect adherence at individual level 
can be categorised into five groups (which will be discussed further) namely patient 
factors, treatment or therapy factors, disease condition characteristics, patient-provider 
or health team relations and social and economic factors (WHO 2003:27-30). In order to 
address adherence holistically, all these factors at individual level need to be assessed 
and appropriate interventions implemented in order to promote good adherence (WHO 
2003:31). 
 
Skovdal et al (2011:296-318) and colleagues explored, interlinked and further distilled 
the five categories to 2 dimensions that of 1) contextual and 2) psychosocial dimensions 
that influence adherence. In that study the authors used the “health-enabling social 
environment model” to better understand relationships and inter-linkages between the 
identified prevalent factors that influence ART adherence (Skovdal et al 2011:314) The 
two categories are however not mutually exclusive, with some overlap between the 
dimensions. In that study the contextual dimensions influencing adherence were 
categorised into: 
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 Material context (Money, food, distance to clinic, transport costs and hospital 
costs). 
 Symbolic context (Stigma, gender roles and diminishing power of traditional 
healers). 
 Relational context (Social support, children and treatment partner/supporter, 
relationship with nurses). 
 Institutional support context (waiting time and opening hours, counselling, 
periods without ARVs, churches and faith, food aid/NGOs, health service 
improvements) (Skovdal et al 2011:301-308). 
 
The psychosocial dimension influencing patient behaviour to adherence was grouped 
into three categories: 
 
 Patient motivation focuses on the factors that nurture a patient either positively 
(facilitators) or negatively (barriers) to taking their medication.  
 Patient participation which requires the active participation of the patient 
shaping both the contextual and psychosocial environments in which they are 
taking ART so that they are conducive to ART adherence. 
 Psychosocial responses to ART looks at how psychologically patients 
respond to their HIV disease and the treatment required (Skovdal et al 
2011:309-312). 
 
2.5.3.1 Patient factors 
 
According to WHO, patient related factors related to the patient’s ability or self-efficacy 
to adhere to medication is closely linked to “resources, knowledge, attitudes, beliefs, 
perceptions and expectations” (WHO 2003:30).  These patient factors also include 
socio-demographic characteristics as well as psychosocial and environmental contexts 
in which patients may be taking their medications in, which can influence their 
adherence to therapy (Skovdal et al 2011:301-315). Whilst ART in many settings 
including Zimbabwe is now provided for free, barriers that are related to the patient of 
different forms still impact on how well patients adhere to medications.   
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Looking at both psychosocial and contextual dimensions affecting adherence, lack of 
resources or poverty at multidimensional levels was identified as one of the most central 
factors affecting adherence (Skovdal et al 2011:301-302). According to the study, 
because patients are counselled about the importance of good nutrition for the drugs to 
work effectively, a combination of lack of adequate food and money or fear of costs 
associated with supplementary foods, presented barriers to adherence (Skovdal et al 
2011:301-303). Other barriers included distance to clinic, transport costs to seek 
medical care and collect monthly drug supplies and hospital administrative fees even 
though the ARV drugs are given for free (Skovdal et al 2011:302-303). 
Disempowerment within the household also undermined adherence, where economic 
dependence on men compromised women’s self-efficacy to adhere to ART (Skovdal et 
al 2011:304-305). 
 
In a qualitative study carried out in Zambia among 60 patients and 12 health care 
workers to assess barriers and facilitators to patients’ adherence to ART identified 
forgetfulness, feeling better, busy work schedules, side effects from medication, 
excessive alcohol intake and pill burden as barriers to adherence (Sanjobo et al 
2008:139). Side effects from medication impacted on patients’ motivation to continue 
taking medication, while feeling better and healthier also gave patients cause to 
discontinue medication (Sanjobo et al 2008:139). Stigma related to fear of being 
identified as an HIV positive person; discrimination and lack of confidentiality were also 
reported barriers to adherence (Sanjobo et al 2008:140-141). 
 
2.5.3.2 Treatment factors 
 
Treatment characteristics that impact on adherence include complexity of the regime, 
frequency of dosage, treatment duration, frequency and severity of side effects, 
frequency in treatment changes and immediacy of beneficial effects (Sanjobo et al 
2008:139; Skovdal et al 2011:311; WHO 2003:30). Most of these factors according to 
Skovdal et al (2011:309) when categorised take the psychosocial dimensions that 
influence adherence, mostly related to patient motivation to take drugs. These 
motivating factors can either be barrier or facilitator to adherence depending on the 
patient’s experience.  Seeing or experiencing health improvements and gaining weight 
can motivate a patient to stay on ART (adherence facilitator), whilst repeated and 
severe side effects (adherence barrier) can lead a patient to stop treatment (Mills et al 
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2006a:2051-2053; Sanjobo et al 2008:139; Skovdal et al 2011:309).  In some studies 
health improvement is also an identified barrier to adherence since some patients 
discontinued their treatment because they felt better (Mills et al 2006a:2051; Sanjobo et 
al 2008:139). Other treatment related factors influencing adherence cited were having 
no time to refill prescriptions or other pharmacy-related problems such as disruption of 
drug access or stock-outs (Mills et al 2006a:2052), dietary restrictions or lack of food 
(Mills et al 2006a:2052; Sanjobo et al 2008:141; Skovdal et al 2011:302-303) to include 
cost for complementary food and  altered meal schedules especially if patient has not 
disclosed their HIV status to family members (Vervoort et al 2007:275-279), complexity 
of regimes (Mills et al 2006a:2051) which may disrupt daily routine schedules and 
finally, taste, size and dosing frequency (Mills et al 2006a:2051). 
 
2.5.3.3 Patient-provider, health system factors 
 
The health care environment that patients receive their ART can affect medication 
adherence.  Sanjobo et al (2008:138-140) identified some of the health services 
characteristics that undermine adherence as lack of information and communication 
between health care provider and patient, time constraints during consultation where 
information given under such environments can be easily misunderstood, lack of 
counselling skills, counselling facilities and perceived lack of confidentiality, lack of 
health systems to allow proper management and follow-up of patients once initiated on 
treatment and the long distances that patients particularly in rural setting have to travel 
to access care and treatment. Skovdal et al (2011:302) classifies these barriers as 
contextual factors that have: 
 
 Institutional support dimension where adherence is influenced by quality of health 
services which includes free and available drugs, good counselling, overall time 
spent at the health facility and opening times that are not prohibitive;  
 Symbolic dimension which focuses primarily on fear and stigma of being identified 
as an AIDS patient, including empowerment issues within the household for the 
female AIDS patients  
 Relational dimension mainly that of the patient and the health providers and lastly  
 Material dimension where access to transport and if available is not too exorbitant 
and the distance of the clinic influences attendance (Skovdal et al 2011:302). 
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2.5.3.4 Socio-economic and cultural factors 
 
Many factors related to socio-economic and cultures are known to influence adherence 
to ART. Some of these factors have a bearing on how positively or negatively 
adherence can be affected. Among the factors include poverty, lack of social, 
emotional/psychosocial support networks, lack of food, long distance from treatment 
centres and associated costs, overcrowding, homelessness or unstable living 
conditions, unemployment, illiteracy, low level of education, culture and beliefs about 
illness, stigma, lack of HIV status disclosure, treatment partner/supporter, gender roles 
and preference of alternative treatments (Mills et al 2006a:2051; Sanjobo et al 
2008:139; Skovdal et al 2011:302; WHO 2003:28).   
 
According to Skovdal et al (2011:298), to better understand how these factors influence 
a patient’s ART adherence behaviour, it is important to understand how these factors 
“are enabled or supported by the wider social environment in which behavioural 
decisions are made.” The authors argue that theories such as information, motivation 
and behavioural skills model, the health belief model and the social cognitive theory that 
have been used to study adherence behaviour have focused at the individual’s level of 
conscious rational choice, de-linked to the environment in which these choices are 
being made. Skvodal et al (2011:298) suggest that depending on the patient’s context, 
“particular forms of behaviour are enabled or limited.”  
 
Among the socio-economic and cultural factors mentioned above, lack of HIV status 
disclosure impacts heavily on adherence since it influences other factors that influence 
adherence. Lack of HIV status disclosure can undermine a patient’s ability to reach out 
for emotional and psychosocial support networks and treatment partner/supporter, 
which are facilitators of adherence. Equally stigma because of fear of being identified 
with the HIV disease can prevent a patient from taking initiatives that can facilitate 
adherence to ART, ‘patient participation’ (Skovdal et al 2011:315).   
 
Non-adherence can undermine treatment success and ultimately long term health.  
Adherence in individual patients can fluctuate over time, influenced by a variety of 
factors discussed. It is therefore important for health care workers to continuously 
engage patients on ART in discussing issues around adherence in order to promote and 
optimise adherence to ART. 
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2.5.4 Strategies to promote ART adherence 
 
Adherence counselling is probably the most important and critical strategy employed in 
preparing and equipping a patient for lifetime behaviour change with respect to taking 
medication to a chronic disease such as HIV. As previously mentioned, once ART has 
been initiated, a patient must adhere to the prescribed medications for treatment to be 
successful. The Zimbabwe guidelines for antiretroviral therapy emphasises the 
importance of good adherence counselling by pointing out that starting ARV treatment 
should not be seen as an emergency and can wait until adherence training/counselling 
has been properly given to the patient (NDTPAC & AIDS and TB Unit MOHCW 
2007:11-12). This approach also embraces the fact that adherence is a dynamic 
process that requires the patient to become knowledgeable on the important 
consequences of both adherence and non-adherence to ART.  Adherence counselling 
is therefore geared at giving the patient information so that they are prepared and they 
fully understand nature of HIV disease, the treatment they are embarking on and 
individual support systems, importance of adherence and strategies for adherence. 
Adherence counselling also aims to help the patient identify potential barriers to 
adherence and how best to address the barriers with an overall goal of ensuring 
patient’s readiness to start treatment and to maintain high adherence in order to 
improve chances of successful treatment outcomes and long-term health (Deeks 
2006:1489). Other strategies to promote adherence include pill boxes (Nachega, Mills & 
Schechter 2010:73; Vervoort et al 2007:277), treatment partner/supporter and support 
groups (Skovdal et al 2011:306) and electronic reminder devices such as cell phones or 
wristwatches or key rings (Nachega et al 2010:73). 
 
2.5.5 Patient retention 
 
For patients to achieve and sustain high adherence levels and minimise risk of 
treatment failure, ART programs must also be able to retain patients on the treatment 
programme.  A meta-analysis assessing patient retention on ART programs in African 
settings involving patients not paying, partially paying and paying in full for treatment, 
reported average weighted mean patient retention rates of 80%, 75% and 62% at 6, 12 
and 24 months respectively (Rosen, Fox & Gill 2007:1694).  In that study, retention was 
defined as “patients known to be alive and receiving highly active ART at end of a 
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follow-up period”, whereas attrition was defined as “discontinuation of ART for any 
reason, including death, loss to follow-up, and stopping ARV medications while 
remaining in care” (Rosen et al 2007:1692).  Kaplan-Meier survival curve analyses for 
all studies showed attrition rate between ART initiation and 6 months at 11%, 19% 
between 6 months and 1 year and 10% between 1 year and 2 years (Rosen et al 
2007:1694-1695).   
 
Contrary to observed ART retention rates in other studies (Mills et al 2006a:2054-2055), 
and supporting the factors attributing to the observed retention rates, a randomised 
controlled study in Zimbabwe reported high rate patient retention in care (Muyingo et al 
2008:468-475). The high retention rate does support the observation that removal of 
barriers to ART retention such as transport costs, clinic fees and non-disclosure can 
facilitate retention in care. 
 
Other factors influencing ART retention include time off work or family duties failure to 
initiate those patients engaged in care whilst waiting for treatment initiation and sicker 
patients (Patel, Hirschhorn, Fullem, Ojikutu & Oser 2010:1-3, 7), failure to re-fill 
prescriptions and distance to the clinic (Patel et al 2010:7). It is therefore important for 
treatment programs to have a system in place to track patients lost-to-follow-up in order 
to retain patients in care and promote adherence to ART (Patel et al 2010:9; Rosen et al 
2007:1698-1699; WHO Global HIV/AIDS response: epidemic update and health sector 
progress towards Universal Access: progress report 2011:84). 
 
2.6 MEASURING AND MONITORING ADHERENCE TO ART 
 
In order to improve HIV treatment outcomes, adherence among patients initiated on 
ART needs to be monitored.  Strategies for measuring and monitoring adherence can 
be divided into immunological and non-immunological methods. 
 
2.6.1 Immunological methods for adherence measurement and monitoring 
 
In resource-constrained countries, immunological or biochemical based measuring 
methods are not always available and or easily accessible to patients on ART. Two 
commonly used immunological based methods for measuring and monitoring ART 
include CD4 cell count and viral load testing. 
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2.6.2 HIV RNA (viral load) quantification 
 
HIV RNA (viral load) is used to measure or estimate the level at which HIV is being 
produced. It is used to measure the amount of virus in the blood and is often used to 
monitor HIV disease progression. Without treatment, HIV replicates or is produced 
unabated, leading to CD4 cell death and high viral load being detected in the blood. 
 
In patients taking HIV treatment drugs, measurement of viral load is used to assess 
virologic suppression and treatment failure which are both indicative of how well the 
antiretroviral drugs are working. Although not routinely offered in clinical care of ART 
patients in Zimbabwe, viral load testing is in limited cases used to investigate patients 
suspected of failing on ART. 
 
In general, a viral load that is below detection levels of the assay defines virologic 
suppression. High adherence level to ARVs is a predictive factor of virologic 
suppression together with other factors which include low baseline viral load (Deeks 
2003:2003), higher baseline CD4 count at ART initiation (Deeks 2003:2003) and 
composition of the ARV regime (Bisson 2008b:107-109).  High viral load in patients 
taking antiretroviral drugs is indicative of treatment failure (Deeks 2003:2002), infection 
with drug resistant virus (Bean 2005:S96, Deeks 2003:2003-2004, Harrigan et al 
2005:339), a weakened immune system (due to CD4 T cell destruction) (Alimonti et al 
2003: 1650) and transient episodes of viremia “blips” (Sedaghat et al 2007:1165). 
 
2.6.3 CD4 cell count quantification 
 
CD4+ T cells play an important role in the immune system of protecting the body 
against infections.  As already mentioned, HIV is known to preferentially infect CD4 + T 
cells. During the HIV replication process, after proviral DNA is integrated into the CD4 
cell’s genomic DNA, the HIV proviral DNA is virtually impossible to destroy (Deeks 
2003:2003-2004). Infected CD4+ T cells can however be destroyed by CD8 cytotoxic 
cells, direct cell death and apoptosis (Alimonti et al 2003:1650-1652).  Progressive CD4 
cell destruction leads to fewer and fewer numbers of circulating CD4+ T cells, high 
levels of HIV copies (high viral load) characterised by a very weakened and 
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compromised immune system, vulnerable to opportunistic infections and HIV disease 
developing into AIDS (Alimonti et al 2003:1650).   
 
Guidelines for ART initiation in most treatment programmes for resource-limited 
countries is a CD4 cell count of <350 cells/cm3 of blood (WHO 2013:94). It is important 
to note that in the absence of viral load testing for OI/ART programmes in resource 
limited countries, WHO recommends both initiation and monitoring of ART based on 
clinical staging and CD4 cell count although programs are urged to reduce reliance on 
clinical failure definitions (WHO 2013:132-134). 
  
Whilst the HIV clinical staging remains an important tool, the revised WHO 2010 
PMTCT guidelines now puts more emphasis on CD4 testing in order to objectively 
identify pregnant mothers as early as 14 weeks whether they require ARV drugs for 
their own health or whether they require prophylactic ARV drugs to reduce risk of HIV 
transmission to their unborn child (WHO 2010a:2).  For that reason and also due to 
innovation and advancement in medical tools, Zimbabwe has adopted use of POC CD4 
testing thereby increasing access of CD4 testing for both the PMTCT and OI/ART 
programmes. For both these interventions, CD4 cell count is used mainly to guide 
clinicians on when to start ART. CD4 cell count is subsequently used to monitor patients 
initiated on art at 6-month intervals for purposes of switching to second-line therapy in 
the event of treatment failure (MOHCW May 2010:11). 
 
Despite continued use of clinical staging and CD4 cell count in monitoring patient 
response to ARV treatment, both have limited sensitivity to detect treatment failure.  
Individual variations in immunological response to ART vary, making CD4 cell count 
changes difficult to interpret  and may misguide clinicians on patient management by 
delaying switching of patients on failing treatment or switching patients too early on 
regimens still effective for viral suppression (Badri, Lawn & Wood 2008:7-8; Bisson,  
Gross, Strom, Rollins, Bellamy, Weinstein, Friedman, Dickinson, Frank, Strom, 
Gaolathe & Ndwapi 2006:1617). 
 
Regardless of how “forgiving” some ARV regimens may be, patients on ARV therapy 
should be encouraged and educated on the importance of near perfect adherence once 
therapy is started.  A study in British Columbia Canada (Wood 2004:266) showed that 
irrespective of baseline CD4 count, adherence was the strongest predictor of CD4 cell 
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count response following ART initiation.  In another study, patients enrolled in a clinical 
trial in Uganda and Zimbabwe showed that higher CD4 cell count at ART initiation 
among HIV positive predicted higher adherence to treatment within the first year and 
more so in the first 12 weeks of treatment (Muyingo et al 2008:472), with the authors 
citing factors such as increased social support, health improvements facilitating 
adherence and clinic attendance easier owing to more strength and “increased ability to 
manage drug side effects” (Muyingo et al 2008:474). A meta-analysis looking at patient 
retention in ARV treatment programs in sub-Saharan Africa found higher rates of 
attrition among programs initiating patients at lower CD4 count when compared to those 
initiating patients at higher CD4 count (Fox & Rosen 2010:12-13). 
 
2.6.4 Non-immunological methods for adherence measurement and monitoring 
 
In research settings, non-immunological tools and methods for adherence measuring 
have been shown to be comparatively easy to use and less expensive, however there is 
need to  better understand how reliable and scalable some of these strategies are for 
routine care at different levels of health care delivery.  
 
Among non-immunological methods to consider when measuring adherence to ART 
that have been used include pill counts, self-reports, pharmacy refill data, electronic 
drug monitoring devices and directly observed treatment.  In clinical settings these 
approaches can be utilised with a goal of identifying patterns of adherence or in 
identifying ART adherence problems and plan appropriate interventions (Bisson et al 
2008a:0786-0789). The challenge in their usage however is that to date, none of them 
is considered as a gold standard and depending on the setting, some methods and or 
tools may be inappropriate and combining different methods may be needed to increase 
accuracy of measurement (Osterberg & Blaschke 2005:489).  
 
2.6.4.1 Pill counts 
 
An adherence monitoring strategy that involves the return of excess pills and or 
medication packaging to the health care provider is known as pill counting. With this 
method, at the patient’s next clinic visit, the health care worker assesses adherence to 
medication by counting the number of pills the patient might still have or not have and 
correlate to the prescription period. Ideally an unannounced pill count in the patient’s 
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home would give a true indication of the patient’s adherence (Kalichman, Amarai, 
Swetsze, Eaton, Kalichman, Cherry, Detorio, Calends & Schinazi 2010:325).  However, 
because of the stigma that may be associated with a home visit and also possible 
confidentiality considerations, pill count assessments are carried out at the health facility 
or during a scheduled outreach clinic setting.   
 
In Zimbabwe Muyingo et al (2008:468-475) assessed adherence using drug possession 
ratio and pill counts among patients in a highly controlled clinical trial. Patients enrolled 
in this study were provided with transport and clinical care for free. Pill count was 
assessed at the health facility during a scheduled visit.  The accuracy of the pill count 
method therefore depended heavily on the trustworthiness of the patient.  Some 
patients in efforts to not disappoint the health care worker and also to assure that more 
medication is dispensed have been reported to dispose of excess doses ahead of these 
scheduled clinic visits (Osterberg & Blaschke 2005:488-489), thereby inflating the 
adherence levels. 
 
The accuracy of the pill count method therefore depends heavily on the trustworthiness 
of the patient.  Some patients in efforts to not disappoint the health care worker and also 
to assure that more medication is dispensed can dispose of excess doses ahead of 
these scheduled clinic visits (Osterberg & Blaschke 2005:488), thereby inflating the 
adherence levels. 
 
2.6.4.2 Self-reports 
 
Self-reporting is one of the most commonly used strategies to monitor patient 
adherence to medication. This method utilises the patient to recall medication taking 
behaviour over a defined period of time which could range from a day to 30 days or 
even more depending on clinical settings. Whilst this method has been shown to 
correlate well with medication intake and viral load (Fletcher, Testa, Brundage, 
Chesney, Haubrich, Acosta, Martinez, Jiang & Gulick 2005:303-305), this method relies 
heavily on the assumption that the patient is truthful and is able to accurately recall their 
medication taking behaviour over the specified period. Other disadvantages 
encountered with use of this method are the tendency by patients to inflate their 
adherence behaviour and patient forgetfulness (Osterberg & Blaschke 2005:489). Self-
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reported adherence monitoring can however be enhanced by using a shorter recall 
period by asking the patient on missed doses in most recent days, utilisation of diaries 
and using a non-judgmental approach (Osterberg & Blaschke 2005:490, Vervoort et al 
2007:277-278) in communicating with the patient. 
 
2.6.4.3 Pharmacy refill data 
 
Of the non-immunological adherence measuring strategies in use, pharmacy re-fill data 
is one of the most objective and relatively least expensive when compared to Event 
Monitoring Systems (MEMS) another objective non-immunological method.  In most 
public health facilities when patients are commenced on ART, they are required to 
collect their ARV drugs from the designated facility pharmacy where they are entered 
into a dispensing pharmacy register. Upon drug collection, the date and regime 
dispensed are recorded and patient is given a date for the next drug collection or refill. 
By assessing the patient’s refill rate or on time drug collection can provide an overall 
indication of the patient’s adherence pattern (Osterberg & Blaschke 2005:488; Nachega 
et al 2006:84).   
 
In an observational cohort study of 2821 patients in South Africa to measure proportion 
of patients achieving viral suppression (HIV RNA less than 400 copies/mL from 1 month 
after HAART initiation till end of follow-up), patients were categorised into 7 categories 
of adherence based on calculated pharmacy refills.  In that study pharmacy refill 
adherence was calculated and expressed as a percentage of the “number of months 
with HAART claims submitted, divided by the number of complete months from HAART 
initiation to death, withdrawal from the program” (Nachega et al 2007:565). Adherence 
strata with 10% increments were used with less than 50% being the lowest category up 
to 100%. A significant dose-response relationship was observed between patients with 
viral load suppression and pharmacy refill adherence for all the 7 adherence categories, 
with rates of sustained viral suppression ranging from 13% in the less than 50% 
pharmacy claim, adherence 25%, 39%, 45%, 59% 69% and 73% respectively for those 
in the 100% category (Nachega et al 2007:566, 569). In that study every 10% increase 
in pharmacy refill adherence for categories greater than 50% was associated with a 
0.10 mean absolute increase in the proportion of patients with virologic suppression 
(Nachega et al 2007:566).  When the authors looked at the time to viral suppression, 
patients in the high pharmacy refill adherence categories had significantly shorter time 
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to viral suppression when compared to those patients in the less than 50% adherence 
category and similarly patients in the 100% pharmacy refill adherence group had 
significantly shorter time to suppression when compared to adherence categories with 
less than 90% adherence (Nachega et al 2007:570).  Over 60% of the cohort 
maintained pharmacy refill adherence that was more than 80% (Nachega et al 
2007:568, 569, 572).  
 
In another study adherence monitoring by pharmacy refills was superior to CD4 cell 
count changes in detecting virological failure at 6 and 12 months for patients initiated on 
NNRTI-based ART among HIV-1 infected adults from nine countries in southern Africa 
who subscribed to a private health care plan (Bisson et al 2008a:0778-0780). Virologic 
failure at 6 months was assessed by pharmacy refill data in the first 3 months of ART 
initiation, and at 12 months, it was the first 3 months post the 6-month follow-up date. 
CD4 cell count change in 6 months was measured between time of ART initiation and 6-
month viral load testing and the 12-month CD4 change was measured from ART 
initiation to the 12-month viral load testing (Bisson et al 2008a:0780).  In that study the 
advantage of adherence value monitoring superseded CD4 cell count because of its 
“overall accuracy in detecting current virologic failure” irrespective of the level of virus 
load used to define virologic failure and the fact that CD4 cell count monitoring identifies 
virologic failure retrospectively, after it has already occurred (Bisson et al 2008a:0780-
0786), clearly suggesting the important and critical role of how pharmacy refill data can 
be used in real-time patient management.  
 
Overall in resource limited settings, pharmacy refill adherence monitoring has been 
suggested as a viable and more useful strategy of early identification of virologic failure 
compared to CD4 cell count which could be utilised by the health care provider to 
screen and prioritise patients who may require viral load testing (Bisson et al 
2008a:0785-0786).   
 
2.6.4.4 Electronic drug monitoring devices 
 
The most common method for adherence monitoring that involves electronic devices is 
called Event Monitoring Systems (MEMS). With this strategy the patient’s medication 
bottle cap is inserted with a computer chip that records the events of opening and 
closing of the medication bottle. For each event, the date and time of the opening and 
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closing and duration of the opening of the medication bottle are recorded (Paterson et al 
2000:22). Data on the chip can be downloaded onto a computer and analysed, allowing 
for adherence to be measured over a continuum. 
 
A prospective observational study at two HIV clinics in Pittsburgh Pennsylvania and 
Omaha Nebraska USA studied the association between protease inhibitor adherence to 
ART using MEMS and patient outcomes both virologic and clinical (Paterson et al 
2000:24). The level of adherence as measured by MEMS was significantly associated 
with risk of virologic failure and hospitalisation for patients with less than 95% 
adherence (Paterson et al 2000:26). Level of adherence also significantly predicated 
changes in CD4 cell counts with patients with greater than 95% adherence managing a 
mean increase of 83 cells/mm3 compared to mean increase of 6 cells/mm3 for patients 
with less than 95% adherence over the course of the study (Paterson et al 2000:24-26).    
 
Usage of the MEMS strategy assumes that with each recorded event, the prescribed 
dose is taken.  If a patient however decides to remove several doses with a single event 
for later ingestion, this may lead to underestimation of adherence or higher non-
adherence rates being recorded (Osterberg & Blaschke 2005:489).  Likewise if a patient 
opens the bottle without taking any doses, this would overestimate adherence 
(Osterberg & Blaschke 2005:489). 
 
With MEMS, one kind of drug is usually used per container, making this method 
expensive for use with triple drug regimens such as those in use with ART and more so 
for resource limited settings.  Another disadvantage of the MEMS strategy is that it only 
works if the patient consistently replaces the cap back onto the bottle after each 
opening.  Also because of the expense and general unavailability makes this adherence 
measuring strategy impractical for resource-constrained countries. 
 
2.6.4.5 Directly observed treatment (DOT) 
 
When directly observed treatment (DOT) strategy was introduced it became standard 
treatment for the management of tuberculosis infections.  This strategy for TB infections 
has been feasible and successful mainly because it is short term and not lifelong 
treatment as that required by HIV infected patients.  The DOT version in the context of 
HIV infections, directly administered antiretroviral therapy (DAART) has primarily been 
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limited to research settings and has simply been deemed not feasible for large-scale 
routine clinical practice (Ford, Nachega, Engel & Mills 2009:5-6, Nachega et al 
2010:72).  The DOT or DAART strategy requires the patient to be physically and 
visually observed (usually by a health care provider) ingesting the antiretroviral drugs.  
It’s use to improve adherence and virologic outcomes has however been suggested for 
HIV infected drug users (Maru, Bruce, Walton, Mezger, Springer, Shield & Altice 
2008:1-2) and perhaps other identified populations at risk of poor adherence (Nachega 
et al 2010:73).  
 
In resource limited settings, reliable and easy to implement methods of measuring 
adherence in ART intervention programmes is essential for success. This study aims to 
retrospectively determine the level of adherence to ART when using pharmacy refills 
and the extent of the relationship between ART adherence when measured by 
pharmacy refills and immunological parameters of CD4 count and HIV-1 RNA levels 
(viral load) among HIV positive patients at Mpilo Central Hospital in Bulawayo 
Zimbabwe.  CD4 cell count is an immunological parameter recommended by the WHO 
to monitor treatment in resource limited settings. 
 
2.7 CONCLUSION 
 
A literature review was conducted to identify, summarise and synthesise research 
previously carried out on HIV and AIDS and treatment with a specific focus on 
adherence to ART. For treatment interventions to be successful, high levels of 
adherence are critical to prevent treatment failure and the development of drug resistant 
viruses. Importance of the HIV life cycle in relation to treatment development strategies 
was highlighted. Treatment guidelines followed by the ART intervention programmes in 
Zimbabwe were discussed. Barriers and enabling factors that influence adherence as 
well as strategies to promote adherence were discussed. Despite lack of a standard 
method of measuring adherence, different strategies and tools used to measure 
adherence were outlined. Pharmacy refill data (a non-immunological parameter) is 
explored for its ability to measure adherence levels to ARV drugs and assess how it 
compares with CD4 cell count an immunological parameter. 
 
In the following chapter, a description of the research design and methods utilised in the 
study to achieve the objectives of the study is presented. 
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CHAPTER 3 
 
RESEARCH DESIGN AND METHODS 
 
 
3.1 INTRODUCTION 
 
This chapter outlines the research design and methods followed in this study. 
 
It begins with a discussion of the research design followed by the description of the 
research methods which included the setting, population, sample and sampling 
procedures, data collection and analysis procedures. Ethical principles that pertain to 
the study were considered. 
 
3.2 THE RESEARCH AIMS AND OBJECTIVES  
 
As indicated in chapter 1, the aims of the study were to determine the level of 
adherence to ART when using pharmacy refills and the extent of the relationship 
between ART adherence when measured by pharmacy refills and immunological 
parameters of CD4 count and HIV-1 RNA levels (viral load) among HIV positive patients 
at Mpilo Central Hospital, Zimbabwe. In order to achieve the aims of the study, the 
following objectives were formulated: 
 
 Describe the level of adherence to ART when measured by pharmacy refills 
compared to CD4 cell count and viral load.  
 Describe the relationship between adherence to ART when measured by 
pharmacy refills, CD4 cell count and viral load.   
 
3.3 THE RESEARCH QUESTIONS 
 
The research questions that guided the study were: 
 
 What is the level of adherence to ART when measured by pharmacy refill 
compared to CD4 cell counts and viral load? 
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 What is the relationship between adherence to ART when measured by 
pharmacy refills, CD4 cell counts, and viral load? 
 
3.4 RESEARCH DESIGN 
 
The plan or “blueprint” of how the researcher intends to collect data for a study in order 
to answer research questions in given conditions is known as the research design 
(Grove et al 2013:214).  The choice of a study design guides the researcher in planning 
and implementing the study in terms of how they go about the selection of a study 
population, sampling methods of measurement, data collection and analysis with the 
main objective of maximising the validity of the study (Grove et al 2013:214-215).  A 
non-experimental, quantitative, retrospective, descriptive and correlational design was 
used for the purposes of this study.  
 
3.4.1 Non-experimental research design 
 
A non-experimental research design was used because the researcher collected data 
without introducing any treatment or changes to the subjects. According to Polit and 
Beck (2012:223), some variables although possible to manipulate cannot be 
manipulated for ethical reasons in human studies.  In this study, withholding treatment 
would be unethical and hence adherence data was collected retrospectively in its 
natural setting to determine level of adherence to ART when measured by pharmacy 
refill compared to CD4 cell counts and viral load and also understand the relationship 
between adherence to ART when measured by pharmacy refills, CD4 cell counts and 
viral load. 
 
3.4.2 Quantitative research design  
 
A positivist paradigm following quantitative approach and research processes was used 
in this study. Quantitative research is a formal, objective, systematic process 
implemented to obtain numerical data for understanding aspects of the world. For 
quantitative research design, structured tools are used to generate numerical data and 
statistics are used to organise and interpret the data collected (Grove et al 2013:23-24). 
Quantitative research processes are objectively constructed and its findings are 
replicable and generalisable (Parahoo 2006:49).  
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3.4.3 Retrospective cohort design 
 
Polit and Beck (2012:224) define retrospective cohort design studies as those 
investigations that try to evaluate an existing condition as a result of a phenomenon or 
event of the past. In that respect, the effect (existing condition) or dependent variable is 
evaluated to see if it can be linked to a reason (event in the past) or independent 
variable. A retrospective, cohort design enabled the researcher to obtain information 
and clarity concerning the status of the phenomena of interest; namely adherence to 
ART in patients initiated on ART between 1st October 2009 and 31st December 2010. 
The objective of this retrospective cohort research approach was to describe the 
relationship between the dependent variable (adherence to ART when measured by 
pharmacy refills) and the independent variables namely CD4 cell counts and viral load 
as they occurred in retrospect.  According to Polit and Beck (2012:725), a dependent 
variable is the “outcome variable of interest” or the outcome measure influenced or 
caused by another variable.  On the other hand, an independent variable is the variable 
that is “believed to cause or influence the dependent variable” (Polit & Beck 2012:730).  
Several other dependent variables of gender, age, marital status, living situation or type 
of residence, employment status and treatment supporter and or disclosure are 
considered and reported in Chapter 4.   
 
Cohort studies have defined time frames of enrolment of a population sample that 
meets specific exposure characteristics or phenomenon and can either be prospective 
or retrospective (Polit & Beck 2012:224-225; Grove et al 2013:309-310).  In a 
retrospective cohort study, exposure status or phenomenon is determined in the past for 
a group/cohort of patients followed over a defined period of time (Polit & Beck 2012:224; 
Grove et al 2013:310).  In this study a retrospective cohort approach was used.  
Patients initiated on antiretroviral therapy between 1 October 2009 and 1 December 
2009 were part of the study.  The rationale for the specified period of treatment (1st 
October 2009 to 31st December 2010) was that patients who would have completed a 
year on ART were likely to have all their records complete by the time the study was 
conducted. The date range selected by the researcher for the cohort also took into 
account a period during which the Zimbabwean economic landscape had “normalised” 
after a serious economic down turn in the preceding three to four years. So during this 
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period there were adequate or normalised ART stocks and treatment was accessible to 
all HIV positive patients. 
 
3.4.4 Descriptive correlational research design 
 
A descriptive correlational research design is used to describe relationships between 
and or among variables in a non-manipulated environment.  According to Polit and Beck 
(2012:226), the aim of a descriptive correlational research design is to describe the 
relationships among variables” without showing or inferring causality. For a descriptive 
correlational research design, the  sample is studied as a single group (Grove et al 
2013:225) and it is further defined by its ability to provide covariation or an account or 
description of relationships that may exist between or among variables and also identify 
patterns of relationships as they occur (Grove et al 2013:225-226).  In addition, 
descriptive studies are capable of observing, describing and documenting “aspects of a 
situation as it naturally occurs” (Polit & Beck 2012:226).  The use of the  descriptive 
correlational design  enabled  the researcher to describe the statistical associations 
between two or more variables namely  pharmacy refill data, adherence to ART and 
CD4 cell count and viral load among a cohort of patients initiated on ART at Mpilo 
Central Hospital OI/ART clinic between October 1 2009 and December 31 2009.  
 
Correlational studies cannot be used to study causality.  The cause and effect cannot 
be stated in correlation studies because the direction of the cause is not known and 
other variables may also be involved in the observed outcome (Polit & Beck 2012:224, 
Grove et al 2013:224-226).  Further, the strength or the degree and direction of the 
relationship between variables can be examined (Polit & Beck 2012:224), although one 
is not able to determine which variable has more influence on the other.  According to 
Polit and Beck (2012:229), one of the strengths of a correlational study design is the 
close to reality presentation of a phenomenon and more importantly is “seldom criticized 
for its artificiality).  Often correlational research designs are used as a basis for further 
and more rigorous experimental studies (Grove et al 2013:225; Polit & Beck 2012:229) 
that may be able to establish causality. 
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3.5 RESEARCH SETTING 
 
The study setting is defined by Polit and Beck (2012:743) as the physical location and 
conditions in which data collection takes place. The study was conducted at Mpilo 
Central Hospital which is a 938-bed government public health institution in Bulawayo, 
Zimbabwe. Because of its size, finding a sufficient sample was not likely to be a 
problem. Mpilo is the only government central hospital located in the Bulawayo 
Metropolitan province in the South West region of the country. It is a   referral centre, 
not only for its province but for 4 other surrounding provinces with HIV prevalence 
indicated as follows: Matebeleland North, (18.3%) Matebeleland South (21.2%), 
Midlands (15.4%) and Masvingo (14.4%) (Zimbabwe National Statistics Agency 
(ZIMSTAT) and IC International 2012).   
 
The Bulawayo health services infrastructure includes 4 hospitals (3 public hospitals 
which are Mpilo Central Hospital, United Bulawayo Hospitals (UBH) and 1 private 
hospital, Materday as well as 19 Bulawayo city polyclinics.  A patient referral system is 
in place with the 19 clinics being the main primary health care providers. All the stated 
health facilities offer HIV counselling and testing, PMTCT services and maternal and 
child health services.   
 
3.5.1 Mpilo Central Hospital OI/ART Clinic 
 
Mpilo OI/ART clinic was started in 2003 as one of the first 5 ART pilot sites in Zimbabwe 
and was also the only public health centre offering treatment and care at no fee. There 
is a dedicated OI/ART pharmacy at the clinic. In addition to the regular Government of 
Zimbabwe funding, the OI/ART clinic at Mpilo hospital was supported by the Médecins 
Sans Frontières (MSF) Spain from 2004.  This organisation whose name means 
“doctors without borders” generally focuses its operations and funding in health 
situations that are in a state of emergency and need special attention to combat or 
arrest further spread of diseases of concern.  The support and funding from MSF 
provided for the clinic towards the HIV and AIDS pandemic and it included staff, ARV 
drugs and other consumables as well as access to laboratory tests including viral load 
testing for those suspected of failing on treatment. In December 2010, MSF Spain 
terminated their operations at Mpilo Hospital.    
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The clinic operates from Monday to Friday from 08:30am to 04:30pm except on public 
holidays and has a standard operating procedure which articulates the day to day 
operations of the clinic. Based on the clinic’s statistics, on average 185 HIV positive 
patients are initiated on ART every month (MoHCW ART register 2009).   
 
At the clinic, patients referred for ART are entered in a Pre-ART register where medical 
and psychosocial issues involved with taking ARVs are addressed.  During this period 
patients may have a CD4 cell count done if they do not already have one.  Counselling 
on good ARV adherence, adequate nutrition, adoption of healthy lifestyles and 
management of any psychosocial factors that may interfere with the patient’s ability to 
access follow-up care is done.  Pre-ART counselling sessions are also used to 
encourage patients to disclose their HIV status and or identify a treatment supporter.  
After appropriate counselling and preparedness assessment, patients at initiation of 
ARVs are entered into ART register and given two weeks supply of drugs.  After two 
weeks, patients are assessed for stability mainly focusing on drug tolerance and 
adherence before a month’s dosage is dispensed.  
 
Patients are initially expected to come to the clinic monthly for re-fills and at every visit 
they are assessed for adherence.  Depending on individual circumstances and drug 
stocks, patients can be given enough drugs for up to three to four months to lighten the 
burden of drug refills. Varied methods of assessing adherence to ART are used namely 
pill counts, self-reports and missed appointments.  Whilst adherence counselling is 
done at every visit, more focused attention is given to patients found to be missing their 
appointments or patients with evident adherence levels lower than 95%.   
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Figure 3.1: Map of Zimbabwe showing Bulawayo city in Bulawayo Province and 
surrounding provinces referring patients to Mpilo Central Hospital 
(Google Images 2012) 
 
 
3.6 RESEARCH METHODS 
 
The research methods applied in this study comprised the description of the population 
selected for the study, procedures and strategies for data collection and analysis. These 
are described in the paragraphs that follow: 
 
3.6.1 Study population 
 
A population is defined as entities be it individuals or objects in which specified 
measurement of interest or defining characteristics are represented (Polit & Beck 
2012:59).  It is not possible to study an entire population hence the use of a target 
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population derived from the population (Grove et al 2013:351). A target is defined as the 
“entire set of individuals or elements who meet the sampling criteria.”  
 
The target population for the study included HIV positive adult patients initiated on ART 
between 1 October 2009 and 31 December 2009 and followed up for 12 months. The 
researcher needs to further identify a population that is accessible. The accessible 
population represents the group from which the sample (sample frame) is taken and it 
provides a sample that generalises to the target population (Polit & Beck 2012:744).  
The accessible population were patients who met the inclusion criteria. 
 
3.6.1.1 Inclusion criteria 
 
Inclusion criteria defines the “characteristics that the subject or element must possess to 
be part of the target population” (Grove et al 2013:353). For this study HIV positive 
patients at an MSF-Spain supported public hospital OI/ART clinic were considered.  
Eligibility criteria included: 
 
 Male and female  HIV positive patients 
 Patients 18 years of age and above 
 Patients  initiated on  ART between 1 October 2009 and 31 December 2009 and 
were followed up for 12 months 
 Patients who had CD4 cell count done on or before ART initiation 
 
Recruitment of all persons seen at the recruitment site meeting the inclusion criteria for 
this study went on retrospectively from October 1 2009 to December 31 2009 and 
followed-up for a 12 month period. The rationale was to choose the latest recruits who 
were likely to present the current trends rather than old patients.  The cohort date range 
chosen by the researcher took into consideration a period during which the 
Zimbabwean economic landscape had “normalised” after a serious economic downturn 
in the preceding three to four years.  The other factor also considered finding a patient 
cohort that had completed a year on ART and were likely to have all their records 
complete by the time of the study conduct. 
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3.6.1.2 Exclusion criteria 
 
Exclusion criteria are the “characteristics that can cause a person or element to be 
excluded from the target population” (Grove et al 2013:353).  The following patients 
were excluded from this study: 
 
 HIV positive patients who were younger than 18 years of age at ART initiation.  
Medical examinations and record forms used with adolescents and young 
children are different and data extracted from these records would not be 
compatible with the sequence of data entry in the ART registers and facility held 
patient records used with the adults. 
 Patients who had ART treatment for less than 12 months. 
 Patients who were initiated on ART prior to 1 October 2009 and after 31 
December 2009.  
 Patients who were initiated on ART with no baseline CD4 cell count and no 
subsequent or follow up CD4 count done within the specified cohort period. 
 
3.6.2 Sample and sampling procedures 
 
It is impractical and close to impossible in terms of time, money and feasibility to study 
the entire population in research.  As a result, a process of choosing part or a subset of 
the population in order to represent the whole population is undertaken (Grove et al 
2013:351-352). This is called sampling.  In conducting research, a sampling plan on 
how to get study participants for the research study is required.  According to Grove et 
al (2013:357), these sampling plans or strategies can either use probability or non-
probability procedures with the overall aim of increasing “representativeness and 
decrease systematic bias”. In this study, probability sampling was used for selecting 
participants for the study. Probability sampling is a technique or a procedure used in 
quantitative research to ensure that each element in the population has an equal and 
independent chance of being selected and achieves representativeness (Polit & Beck 
2012:280). The researcher readily had access to all records (n=118) of patients who 
met the inclusion criteria.  The sample size of 118 was manageable and adequate for 
data analysis. As a result no sampling procedures were applied for this study.  
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The sample frame was the ART register of HIV positive patients seeking HIV care and 
treatment at Mpilo Central Hospital.  
 
Figure 3.2 shows that at Mpilo Central hospital, a total of 460 patients were initiated on 
ART between October and December 2009 as follows 165 (36%) in October, 182 
(39.5%) in November and 113 (24.5%) in December 2009. The number of patient 
records that met the inclusion criteria for this study was 118 and 242 were excluded 
because of incomplete identification, absence of baseline CD4 cell counts and absence 
of follow-up CD4 cell counts.  
 
 
Figure 3.2: Flow chart for patients initiated on ART between October and 
December 2009 
  
Patients initiated on ART in October
165(35.8%)
Patients initiated on ART in December
113(24.6%)
Patients initiated on ART in November
182(39.6%)
Cohort Total
n=460
Patients with follow-up CD4 count
118(25.7%)
Patients with baseline CD4 count
144(31.3%)
Patients with incomplete IDs
9(19.8%)
Patients with complete IDs
369(80.2%)
Patients with no baseline CD4 count
225(48.9%)
Patients without follow-up CD4 count
26(5.6%)
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3.6.3 Data collection 
 
Data is described as information that is gathered from counts, measurements 
responses or observations (Grove et al 2013: 507). Various methods for collecting data 
are used in research studies with the aim of fulfilling research objectives. A structured 
data collection process was adopted in this research study. The structured approach 
was appropriate because it facilitated the collection of data that was easy to analyse.  
Data was extracted from the facility health cards, facility OI registers and pharmacy 
dispensing registers.  
 
3.6.3.1 Data collection instrument 
 
With the assistance of the statistician (Annexure H), the researcher designed the data 
collection instrument (Annexure E).  The instrument was computerised into an Excel 
spread sheet (Microsoft). Information was categorised into two sections namely socio-
demographic and clinical data.  The socio-demographic section of the data collection 
instrument included patient OI/ART number, marital status, employment status, gender, 
type of residence, number of years HIV status was known to the patient (calculated from 
date HIV test was done and date ART was initiated), OI/ART entry point or referral 
source, treatment supporter and age at ART initiation.  
 
The clinical data section captured date of ART initiation and subsequent follow-up dates 
of pharmacy refill, weight, height, ARV regimen initiated, switch regime, date of switch 
and reason, pregnancy, date of next appointment, WHO staging and CD4 cell counts. A 
CD4 count at ART or before ART initiation was recorded.  Follow-up CD4 cell count 
were recorded and if more than one follow-up CD4 count was available, the latest CD4 
cell count recorded closest to the end of the follow-up period was used to calculate 
percent CD4 cell count gain.  A 50% CD4 cell count gain was used to indicate immune 
recovery. Adherence level was based on the actual date of prescription re-fill thus 
subtracting the actual day of prescription re-fill from the date of next appointment. A 
seven day grace period was applied for all participants not collecting their prescription 
on the exact date of the next appointment.  If a participant however collected their 
prescription earlier than the date of the next appointment, these were considered 
adherent and or on-time collections. Although weight and height were recorded 
consistently for the majority of the patients, this was not the case for the follow-up 
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period. For the follow-up period, both variables of height and weight were not being 
recorded systematically and therefore were dropped from analysis.  
 
3.6.3.2 Data collection process 
 
The researcher was responsible for data collection and capturing. Patients OI/ART 
numbers were double entered using different formats to ensure correct entry. 
 
Patient data was transcribed from the ART register, patient facility held health cards and 
pharmacy dispensing registers kept in the pharmacy into the data collection excel 
spread sheet. Although electronic data captured using the Fuchia software by MSF 
Spain was availed to the researcher, the data could not be extracted for analysis 
because staff with access codes and knowledgeable in extracting the data left when 
MSF Spain support to the OI clinic ended in December 2010.  Most of the viral load data 
which was supported by MSF Spain was captured in this database.  Staff able to extract 
this data is now based at different MSF Spain supported facilities.  However due to the 
logistical issues of accessing the services of the capable members of staff to extract the 
data and time constrains related to completing this research study the researcher 
decided to drop this variable from analysis.  This also resulted in the researcher not able 
to complete one of the original secondary objectives of this research study that of 
comparing adherence using pharmacy-refills and viral load.   
 
During the pre-testing exercise of the research instrument, the researcher noted that 
data extraction for adolescent patients was difficult.  Often adolescent patients were 
recorded in adult registers. Facility held patient files were also found among adult files 
and investigations and record forms were different from those used with adults.  For 
those reasons the researcher decided to limit the study population to adults.  
 
Again during the pre-testing procedures of the research instrument, instead of 
transcribing data onto the data collection instrument for subsequent entry into the 
computer, data fields on the form were put into an Excel spread sheet and data 
captured directly from source document in an effort of reducing the chances of 
transcription errors. However this proved to be a challenge due to the need to use and 
refer to different data sources.  As a result, the researcher reverted to capturing the data 
onto the data collection instrument with subsequent computer data entry.  Some of the 
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data sources were photographed and the researcher cross-checked all data entered 
against source documents.   
 
3.6.3.3 Use of routinely collected medical data 
 
With relevant ethical approval, research data involving human subjects in the health 
sector can be obtained from data routinely collected (Grove et al 2013:517) as part of 
direct service provision of patient care, monitoring and or evaluation of health care 
delivery services.  Researchers can make use of “hospital records, patient charts, 
physicians’ order sheets, care plan statement” as a rich data source to answer certain 
research questions (Polit & Beck 2012:190) which may involve questions on “utilisation, 
appropriateness, process and outcome of care” (Worster & Haines 2004:187).  The data 
used in this study were collected on-going as part of HIV care and treatment service 
provision at Mpilo OI/ART clinic.  
 
 Advantages of using routinely collected medical data  
 
Using routinely collected data as the main source of information in research studies is 
advantageous in that data is already collected and readily available for careful analysis 
(Polit & Beck 2012:190; Worster & Haines 2004:187).  Reviewing medical records 
enables researchers to address research question which are otherwise either 
impractical or unethical or both with a prospective research design (Worster & Haines 
2004:187; Polit & Beck 2012:190).   
 
 Disadvantages of using routinely collected medical data  
 
According to Polit and Beck (2012:190), when using routinely collected data, the main 
biases to be aware of are selective deposit and selective survival which both address 
“how representative” the medical records are.  The other disadvantage of data gathered 
by reviewing medical records is that of poor quality due to missing records, incomplete 
records and or incorrect record entries.  For this study selective deposit and selective 
survival were not encountered since all records for the study cohort were systematically 
entered in standardised OI/ART registers and other monitoring and evaluation tools 
developed by the Ministry of Health and Child Welfare of Zimbabwe for all patients 
seeking HIV care and treatment at Mpilo OI/ART clinic.  
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The researcher encountered poor recording of data and some variables could not be 
recorded because of missing data on patients’ medical records.  This was particularly 
prominent with viral load data.  Very few patient medical records had viral load data 
captured.  Viral load testing was supported by MSF and data captured into the Fuschia 
database.  As indicated in paragraph 3.6.3.2, it was not possible to access the Fuschia 
database.   
 
3.6.4 Data analysis 
 
Statistical data analysis was conducted using Stata SE release 10 (STATA Corp, 2007).  
Data on patients who remained or continued, died or transferred out over the 12 months 
follow-up period after ART initiation were analysed. The data collected was analysed to 
ascertain adherence levels using pharmacy refills, which is a non-immunological 
adherence measurement parameter and correlated to immunological parameter of CD4 
count.   
 
Descriptive statistics of means, frequencies and percentages were used to describe and 
summarise the data.  Association between variables and level of significance was done 
using the Chi-square test and a Chi-square distribution table to calculate the p-value (α 
=0.05 level of significance). The effect of adherence on CD4 cell count gain was 
investigated using logistic regression analysis. Unadjusted and adjusted odds ratios for 
50% CD4 cell gain or immune recovery were calculated using univariate and 
multivariate logistic models. In the adjusted model gender, age, WHO clinical stages 
were used for adjusting the odds of adherence. The study supervisor and statistician 
assisted the researcher with data analysis and interpretation.   
 
3.7 VALIDITY AND RELIABILITY  
 
Validity and reliability can be seen as the quality assurance strategies that have to be 
observed and taken into consideration for a sound research study. Polit and Beck 
(2012:336) define validity as the extent to which the instrument measures what it is 
intended to measure and reliability as the degree of consistency with which the 
instrument measures the target attribute. 
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3.7.1 Validity 
 
In quantitative research, validity is derived from the assumption that there is only one 
reality, which can be viewed objectively, controlled and manipulated. Face validity refers 
to ‘whether the instrument looks as though it is measuring the appropriate construct’ 
while content validity concerns ‘the degree to which an instrument has an appropriate 
sample of items for the construct being measured’(Polit & Beck 2012:336). Due 
attention was paid by the researcher in the development of the data collection 
instrument to ensure that the items included were representative of what needed to be 
elicited (ART adherence) in accordance with the objectives of the study. The following 
measures were taken to ensure both face and the content validity of the instrument: 
 
 Examination of the instrument by the researcher’s supervisor and a professional 
statistician.  
 The data collection instrument was pre-tested on data from the same data 
sources to be used for the study but on patients (n= 20) not included in the study.  
During this exercise the researcher noted that data extraction for the variables on 
the data collection instrument for adolescent patients was difficult.  Often 
investigations and record forms were different from those used with adults.  For 
those reasons the researcher decided to limit the study population to adults. For 
the most part data entry fields used on the research instrument tried to follow the 
same order as that found in the source documents mainly the ART register in 
order to facilitate easy and accurate data recording (Worster & Haines 2004: 
189). 
 
Construct validity, which are the relationships that exist for variables under study (Grove 
et al 2013:200; Polit & Beck 2012:248) considered adherence to ART, and 
immunological response when measured by increase or decrease in CD4 cell counts. In 
this study a data collection instrument was used to gather patient data on adherence, 
which was the patients’ consistent collection of ARVs (dates of collection) from the 
pharmacy at the stipulated time intervals.  Non-adherence was considered for patients 
who failed to collect ARVs within the stipulated time interval. 
 
External validity addressed how well a study sample represented the population under 
study by looking at the extent to which the results can be generalised beyond the 
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sample used in the study (Grove et al 2013:202), the “extent to which it can be inferred 
that relationships observed in the study hold true over variations in people, conditions 
and settings” (Polit & Beck 2012:250).  The relationships that exist for variables under 
study considered adherence to ART, and immunological response when measured by 
increase or decrease in CD4 cell counts. Because participants or the patient cohort for 
this study were recruited from an MSF supported site where HIV and AIDS dedicated 
physicians oversaw the OI/ART programme, and the extra funding that MSF provided 
for the running of the OI/ART program; patients seen in this health facility might have 
experienced less drug stock outs, had access to better health services and it is possible 
that they would have had higher adherence levels when compared to patients seeking 
the same services in similar government or public health facilities; which may result in 
low external validity.   
 
Adherence to ART captured on the data collection instrument by dates suggests that 
patients’ collected ARVs (pharmacy refill) should reflect the patient’s immunological 
response as data captured by the CD4 cell counts.  For patients who are adherent to 
ART, the measurement tool should detect immunological recovery by an increase in 
CD4 cell count and vice versa. Further adherence to ART is associated with virological 
suppression (as indicated in reduced or non-detectable viral load) and immunological 
reconstitution (as indicated by an increase in CD4 counts) (WHO 2003:95).  In this 
study non-adherence is defined by failure to collect ARV drugs from the pharmacy at 
the prescribed or anticipated drug pick interval.  Pharmacy refill data that was collected 
in this study was only compared to immunological parameters of adherence measuring.  
Virological data could not be collected as already discussed.  It was anticipated that 
patients who were adherent as indicated by consistent and on time ARV pharmacy refill 
record would have an increase CD4 cell count. According to the national ART treatment 
guidelines, a 50% fall in CD4 cell count from on-treatment peak or persistent CD4 cell 
count below 100 cells/mm3 is indicative of immunological failure.   For this study, 
immunological recovery or CD4 cell recovery is defined by a CD4 cell count gain of 50% 
or greater at least 12 months after ART initiation. 
 
3.7.2 Reliability of the data collection instrument and data quality control 
 
In order to ensure that information is collected and recorded accurately the research 
instrument used must be reliable.  According to Kimberlin and Winterstein (2008:2277), 
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reliability of an instrument takes into account the consistency, stability and repeatability 
of measurements.  It is anticipated that if the research instrument is reliable and is 
administered at a different time, it would produce the same results.  To ensure reliability, 
data for all patients recruited into the study were transcribed from source documents 
onto a data collection  instrument  by the researcher thereby optimising interrater 
reliability of the instrument (Kimberlin & Winterstein 2008:2277-2278). The patient 
OI/ART number was double entered in different formats and then compared for 
accuracy. In addition photographic images of the source documents for the cohort 
period were taken and computerised for easy access and subsequent verification and 
completeness.  Data cleaning and verification especially for dates that did not make 
sense or that were miscomputed or wrongly entered in the source documents were 
done before data was analysed to ensure reliability in this study. 
 
3.8 ETHICAL CONSIDERATIONS 
 
In research there are certain ethical guidelines or principles that have to be observed in 
order to protect the rights of the participants and also to ensure the general ethical 
conduct of the study.  Respect, beneficence and justice are the overarching human 
rights principles that need to be considered in research that involves human subjects 
(Polit & Beck 2012:152; Grove et al 2013:162).  Embedded in these principles are the 
rights to (1) privacy (2) anonymity and confidentiality (3) fair treatment and protection 
from discomfort and harm and 4) self-determination (Polit & Beck 2012:152-15; Grove 
et al 2013:162-174).  The ethical principles that were applied in this study include: 
 
3.8.1 Ethical approval 
 
In Zimbabwe health related research has to be approved by the Medical Research 
Council of Zimbabwe (MRCZ).  Moreover, studies that involve contact with patients are 
required to have approval by the respective authorities where the study would have had 
patient contact.  There was no direct patient contact in this retrospective study and 
patients’ data was de-identified.  Ethical approval to conduct the study was sought from 
the Medical Research Council of Zimbabwe (MRCZ) (Annexures C & D), Mpilo Hospital 
Ethics Committee (Annexures A & B) and the higher degrees committee of the 
Department of Health Studies at the University of South Africa (UNISA) (Annexure F).  
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Permission and support was also sought from the Ministry of Health and Child Welfare 
AIDS and TB Unit (Annexure G). 
 
3.8.2 Anonymity and confidentiality 
 
When information is collected from participants involved in a research study, it is the 
researcher’s responsibility to maintain and uphold that individual’s privacy.  In research, 
assuring anonymity and keeping all data collected confidential can maintain the right to 
privacy.  According to Grove et al (2013:172), anonymity in research is assured when 
“subject’s identity cannot be linked, even by the researcher, with his or her individual 
responses”.  Further, upholding and assuring participants’ right to privacy requires that 
the information collected is kept confidential.  Parker (2005:186) maintains that 
respecting patient confidentiality and autonomy are the main ethical issues to be 
considered when using patient records without consent. With respect of patient 
confidentiality, the risk/benefit ratio posed by carrying out the study should be 
considered, especially for studies already deemed low risk. If the benefits outweigh the 
risks, studies on patient records with no consent are allowed (Parker 2005:184-185). 
Likewise respect for autonomy and privacy when using patients records without consent 
is justified in part for those situations where not carrying out the study poses “serious 
risk to others”; and also on the grounds that patients may “legitimately” and without 
having been explicitly consulted be expectant that their data may be put to research 
(Parker 2005:185). It is the researcher’s responsibility to make sure that confidentiality 
is maintained during data collection and analysis (Grove et al 2013:172).  In this study 
use of patient records was done on routinely collected data as part of on-going service 
provision.  The researcher viewed this as a rich source of information on adherence 
which needed thorough analysis and could better inform OI/ART service delivery at 
Mpilo Central Hospital and possibly other similar health care delivery institutions in 
Zimbabwe.  Only the OI/ART number was recorded for each patient in this study to 
ensure that the data collected could not be linked with the patient.  No patient identifying 
information was collected.  All database information was password protected and only 
authorised staff had access to the study information.   
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3.8.3 Justice 
 
In order to uphold the principle of justice, the researcher made use of the predetermined 
eligibility criteria to select participants for the study to ensure proper representation in 
the research samples and respect for diversity in terms of age and gender (Holloway & 
Wheeler 2010:55). 
 
3.9 CONCLUSION 
 
This chapter addressed the research design and methods, taking into consideration the 
study population, data collection and ethical considerations.  Data on a three month 
adult cohort of HIV positive patients initiated on ART between October and December 
2009 were retrospectively collected from facility held registers and patients’ medical 
records. Data analysis on a total of 118 patients meeting the inclusion criteria was 
undertaken. Chapter 4 presents the results and discussion. 
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CHAPTER 4 
 
ANALYSIS, PRESENTATION AND DESCRIPTION OF RESEARCH 
FINDINGS 
 
 
4.1 INTRODUCTION 
 
The analysis of data and the description of the research results are presented in this 
chapter. The chapter begins with data management and analysis followed by the 
presentation of the results of the participants’ socio-demographic data and the 
description of the level of adherence to ART when measured by pharmacy refills 
compared to CD4 cell count. In the last part of the chapter the relationship between the 
respondents’ adherence to ART when measured by pharmacy refills and CD4 cell count 
is described. 
 
4.2 DATA MANAGEMENT AND ANALYSIS 
 
Data on ART adherence levels were extracted from the facility health cards, facility OI 
registers and pharmacy dispensing registers kept in the pharmacy by means of a data 
collection instrument which was computerised into a Microsoft Excel spread sheet. Data 
were collected from the records of patients initiated on ART between 1 October 2009 - 
31 December 2009 and were followed up for 12 months. Patients OI/ART numbers 
were double entered using different formats to ensure correct entry. Prior to data 
analysis, data cleaning and verification were done and some of the data sources were 
photographed to enable the researcher to cross-check all data entered against source 
documents. The raw data were kept safe and confidential, locked up with no 
unauthorised access.  
 
Data analysis was conducted using Stata SE release 10 (STATA Corp, 2007).  Data on 
patients who remained or continued, died or were transferred out over the 12 months 
follow-up period after ART initiation were analysed. Descriptive statistics were used.   
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4.3 RESEARCH RESULTS  
 
The results of the study are presented in the order in which data were collected, starting 
with the socio-demographic data followed by the clinical data.  
 
4.3.1 Socio-demographic data 
 
The participants’ socio-demographic data that were collected included age, gender, 
marital status, employment status, type of residence, number of years HIV status known 
to patient, OI/ART entry point or referral source and treatment partner. The purpose of 
eliciting such information was to ensure that the participants met the inclusion criteria 
and to secure a descriptive profile of participants so as to ensure a basis for data 
analysis in relation to other sections of the data collection instrument as per the 
objectives of the study. In table 4.1, the age, gender, marital status, employment status 
and type of residence of participants are shown. 
 
 
Table 4.1: Participants’ age, marital status, employment status and 
type of residence at ART initiation by Gender (n=118) 
Category Females % Males % Total 
Age  
18-24 3 2.54 7 5.93 10 
25-29 4 3.38 17 14.40 21 
30-34 5 4.23 20 16.95 25 
35-39 3 2.54 21 17.79 24 
40-44 5 4.23 5 4.23 10 
45-49 5 4.23 5 5.23 10 
>50 13 11.01 5 5.23 18 
 
38 32.20 80 67.80 118 (100%) 
Marital status 
 
Married 23 19.49 47 39.83 70 59.3  
Single 7 5.93  12 10.17 19 16.1 
Widow 4 3.38 12 10.17 16 13.6 
Divorced 1 0.84 1 0.84 2   1.7 
Separated 2 1.69 7 5.93 9   7.6 
Not stated 1 0.84 1 0.84 2   1.7 
 
38 32.20 80 67.80 118 100% 
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4.3.1.1 Age, marital status, employment status and type of residence of 
participants 
 
 Age 
 
The age of patients enrolled in this study ranged from 18 to 71 years with an overall 
mean age of 36.9 years.  The mean age for men was 34.2 years and 42.5 years for 
women 
 
 Marital status 
 
As shown in table 4.1, the number of participants who were married at the time of ART 
initiation was 70 (59.3%), 47(39.83%) of which were men and 23 (19.49% were women. 
Nineteen (16.1%) participants were single, 16 (13.6%) were widowed, 2 (1.7%) were 
divorced, 9 (7.6%) were separated and the marital status of 2 (1.7%) participants was 
not known.  
 
 Employment status 
 
A large number of participants 82 (69.5%) was unemployment at the time of ART 
initiation followed by 23 (19.8%) who were formally employed. Nine (7.61%) participants 
were self-employed, 1 of the participants was a student and the employment status of 3 
(2.5%) participants was not recorded. 
 
Employment status 
 
Unemployed 17 14.40 65 55.08 82     69.49 
Self employed 5 4.23 4 3.38 9       7.63 
Formally employed 14 11.86 9 7.62 23      19.49 
Student 1 0.84 0 0.00 1      0.85 
Not stated 1 1.69 2 0.84     3     2.54 
 
38 32.20  80 67.80 118   100% 
Type of residence  
 
Own 18 15.25 29 24.57 47     39.87 
Rent/Relative 15 12.71 37 31.35 52    44.03 
Not stated 5 4.23 14 11.86   19    16.10 
 
38 32.20 80 67.80  118     100% 
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 Type of residence  
 
As shown in table 4.1, a total of 52 (44%) lived in rented accommodation or lived with a 
relative while 47 (39.8%) patients owned their residence at the time of ART initiation. 
The type of residence for 19 (16.1%) patients was not recorded. 
 
4.3.1.2 Number of years HIV status was known to the participants 
 
Figure 4.1 shows the years (in days) that the study participants had known their HIV 
status when initiated on ART.  The number of days was calculated as discussed in 
chapter 3 paragraph 3.6.3.1 by subtracting the date HIV test was recorded to have been 
done from the date ART was initiated.  Participants in this study had known their HIV 
status for a mean period of 6 months with a range of 5 days to 5.7 years. The data 
shows that 19% (n=22) were initiated on ART after having known their HIV status in 2 
months, 15% (n=18) after 1 month and 15% (n=18) after 3 months. Overall majority of 
the patients (68%) were initiated within the first year of knowing their HIV status.  
Another 10% were initiated on ART more than a year after knowing their HIV status with 
one (1) participant having known their HIV status for close to 6 years.  A total of 26 
(22%) of the participants did not have the date of HIV testing recorded. 
 
 
 
 
 
 
 
 
 
Figure 4.1:  Years HIV status known to the participant 
 
The time between knowing one’s HIV status and starting ART is critical in making sure 
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maintained. This is important in that patients eligible for ART initiation are not lost to 
follow-up and or die before interventions can be rendered (Nachega 2007:571, Nachega 
2010:74-75). Furthermore, patients who start ART early or before they are too ill, are 
more likely to be adherent (Nachega 2006:82-83).   
 
4.3.1.3 OI/ART entry point or referral source 
 
Table 4.2 shows the OI/ART entry point. 
  
Table 4.2:  OI/ART Entry point or referral source (n=118) 
Reason Frequency % 
Voluntary Counseling and testing (VCT) 14 11.86 
Hospital/Illness 50 42.37 
Tuberculosis (TB) 6 5.08 
Ante-Natal Clinic (ANC) 28 23.73 
Spouse/Partner HIV positive 10 8.47 
Child HIV positive 8 6.78 
Not stated 2 1.69 
Total 118 100.00 
 
A large number of patients 50 (42.4%) were referred for ART initiation after having been 
hospitalised or experienced some illness followed by 28 (23.7%) referred by the ANC 
and 14(11.9%) reporting VCT as a point of entry for ART treatment.  The numbers of 
patients reporting having an HIV test done because either a spouse or child had tested 
positive were 10(8.5%) and 8 (6.8%) respectively.  
 
4.3.1.4 Treatment supporter 
 
The significance of having a treatment supporter is that the HIV status has been 
disclosed. Figure 4.2 shows the participants’ treatment supporters. 
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Figure 4.2:  Treatment supporter 
 
As shown in figure 4.2, 96 (81.4%) participants had treatment supporters, the majority of 
which were spouses, followed by other, siblings and parent.  There were 2(1.7%) 
patients who did not have a treatment supporter while 20(16.9%) patients’ records did 
not have records of treatment supporter data.   
 
4.3.1.5 Age at ART initiation  
 
Presented in (figure 4.3), are the ages of the participants at ART initiation. Majority of 
the participants (85%) were between 18 to 49 years old. Fifteen percent (15%) of the 
participants were over the age of 50 years.   
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3:  Age at ART initiation 
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4.3.1.6 Summary of the results of the socio-demographic data  
 
Characteristics of the participants for this study are presented in Table 4.1.  Of the 118 
participants 67.8% were male and 32.2% were female. The study participants’ ages 
ranged from 18 to 71 years, with a mean age of 36.9.  Majority of the participants 
(59.3%) were married at ART initiation, 16.1% were single, 13.6% were widowed, 1.7% 
were divorced, 7.6% were separated and 1.7% did not have marital status recorded. 
Close to two thirds 69.5% of the study participants were unemployed, 7.63% were self-
employed, 19.5% were formally employed 1 participant was a student, 1 participant was 
employed in the private sector and 3 participants did not have employment status 
recorded.  Most of the participants (44%) in this study lived in rented accommodation or 
lived with a relative, 39.9% owned the residence they had at ART initiation and 16.1% 
participants did not have their type of residence recorded.   
 
The duration that participants in this study had learnt of their HIV status ranged from 5 
day to 5.7 years with a mean period of 6 months.  Most participants were initiated on 
ART within a year of knowing their status, 10% more than a year after knowing their 
status and 1 participant was initiated on ART close to 6 years after being tested HIV 
positive.  Duration of having known the HIV status could not the established for 22% of 
the participants because the date of HIV testing was not recorded.   
 
The main entry point or referral source for ART initiation in this study was due to illness 
or having being hospitalised (42.4%).  ANC referred 23.7% of the participant for ART 
initiation, VCT 11.9% and TB illness 5.1%.  Entry for ART treatment because either 
spouse/partner or child had tested HIV positive accounted for 8.5% and 6.8% of the 
participants respectively.  A very high proportion of the participants (81.4%) had a 
treatment supporter mostly close members of the family of spouses, siblings or parents. 
Only 1.7% of the participants were recorded as not having a treatment supporter and 
16.9% participants did not have treatment supporter data recorded. 
 
4.3.2 Clinical data 
 
Clinical data collected from the participants in this study were the date that the 
participants were initiated on ART and the subsequent pharmacy refill dates, height and 
weight at ART initiation, WHO HIV/AIDS clinical stage, ART regimen initiated, ART 
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regimen switch and reasons for the switch and CD4 cell count at ART initiation and for 
the follow-up period.  Variables collected in this section were used to measure and 
describe adherence level to ART when measured by pharmacy refills and CD4 cell 
count.    
 
4.3.2.1 The dates of ART initiation  
 
The dates of the participants’ ART initiation are shown in figure 4.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4:  Dates of ART initiation 
 
According to the findings, all participants met the inclusion criteria of ART initiation of 1st 
October – 31st December 2009. 
 
4.3.2.2 Weight and height of participants 
 
According to the guidelines for antiretroviral therapy in Zimbabwe, weight measurement 
is recommended and required for adolescents (less than 25 kg) and paediatric patients 
for ART initiation since dosages are determined by weight (NDTPAC & AIDS and TB 
Unit MOHCW 2010:17). For adult patients weight measurement is not a requirement for 
ART initiation. It is a good clinical practise to weigh patients seeking health care 
regardless of their HIV status but more so for HIV positive patients since wasting is a 
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common feature (NDTPAC & AIDS and TB Unit MOHCW 2010:62-63).  Weight 
measurements are also useful in the management of patients on ART to ascertain if 
there is improvement in health often indicated with weight gain.  Usefulness of height 
measurements have been indicated mainly for HIV positive infants and children where 
stunting has been observed (NDTPAC & AIDS and TB Unit MOHCW 2007:28).  
 
Table 4.3 shows the anthropometric measurements of weight and height of the study 
participants at ART initiation.  Mean weight for females was 59.7 kg and 58.2 kg for 
males.  Mean height for females was 162 cm and 171.5 cm for males.  The slightly 
higher mean weight in females than males could be due to the fact that 25 (65.8%) of 
the women in this study were pregnant and an additional 15.8% (n=6) although 
pregnancy was not overtly recorded, were indicated to be ANC or PPTCT patients and 
so were potentially pregnant or had recently been pregnant.   
 
Follow-up weight and height measurements were not collected for this study because 
these were not being systematically recorded in the participants records.  
 
Table 4.3:  Weight and height measurement at ART initiation (n=118) 
  
Mean weight (kg) 
Weight Range 
(kg) 
Weight not 
recorded 
Total 
Male 58.2 (n=34) 35 -74 4 38 
Female 59.7 (n=79) 35 - 92 1 80 
Total 113 
 
5 118 
     
  
Mean height (cm) 
Height Range 
(cm) 
Height not 
recorded 
Total 
Male 171.5 (n=33) 152 -184 5 38 
Female 162 (n=72) 150 - 180 8 80 
Total 105   13 118 
 
4.3.2.3 WHO staging  
 
The WHO has established a set of clinical guidelines based on clinical manifestations 
that help in the determination of eligibility for treatment and management of HIV 
patients. These clinical manifestations present themselves mainly as opportunistic 
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infections plus other HIV defining illnesses. As discussed in Section 2.3.2.1, the WHO 
has divided the stages into four, with each stage having specified clinical conditions and 
or symptoms used in assessing HIV disease progression (National Drug & Therapeutics 
Policy Advisory Committee (NDTPAC & AIDS and TB Unit MOHCW 2010:62).  These 
guidelines have been widely utilised in many resource poor settings owing to lack of 
adequate trained medical personnel and laboratory infrastructure including equipment 
and reagents.   
 
Table 4.4: WHO HIV clinical staging at ART initiation 
(n=118) 
Stage Frequency Percent 
Stage I 14 11.9 
Stage II 23 19.5 
Stage III 58 49.1 
Stage IV 16 13.6 
Not stated 7 5.9 
Total 118 100.0 
 
Table 4.4 shows the WHO clinical stages that the study participants were in at ART 
initiation. The majority of the patients 58 (49.2%) in this study were classified as stage 
III followed by 23 (19.5%) in stage II, 16 (13.6%) in stage IV, (n=16), 14 (11.9%) in 
stage I and the clinical stage for 7 (5.9%) participants was not recorded.  
 
4.3.2.4 ART regimen initiated 
 
Data from this study showed that all patients were initiated on ARVs for the period 1st 
October to 31st December 2009 and were followed-up for 12 months (December 2010). 
As indicated in chapter 2, the National ART guidelines recommend a combination of two 
NRTIs and one NNRTI as first-line drug regimens. Table 4.5 shows the ARV drugs 
grouped according to the drug class they belong to include PIs which are recommended 
for inclusion for patients indicated for second line treatment.   
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Table 4.5: ARV drug classifications 
Drug Class Acronym Generic Name 
NRTI 
3TC lamivudine 
AZT Zidovudine 
D4T Stavudine 
TDF Tenofovir 
NNRTI 
NVP Nevirapine 
EFV Efavirenz 
PI 
LPV/r Lopinavir/ritonavir 
RTV Ritonavir 
 
 
As shown in Figure 4.5 the data revealed that all 118 patients were initiated on ART 
according the National ART guidelines.  On initiation 63% (n=74) of the patients were 
on D4T + 3TC + NVP, 19% (22) were on AZT +3TC + NVP, 12% (n=14) D4T + 3TC + 
EFV, 2% (n=3) were on TDF+3TC + EFV, 2% (n=3) were on AZT +3TC + EFV and 2% 
(n=2) were on TDF+3TC + NVP. 
 
 
Figure 4.5:  ART regimen initiated 
 
4.3.2.5 ART regime “switch” 
 
High adherence to ART is important in assuring good health outcomes and prevents 
drug failure.  Patients may among other reasons fail to adhere to their treatment 
regimens because of factors related to the treatment itself.  An ART patient may not 
adhere to treatment due to toxicities and or side effects of the treatment regimen.  As 
discussed earlier, not adhering to ART can provide an environment for viral mutations 
63% 
19% 
12% 
2% 2% 2% 
ART regimen initiated 
D4T + 3TC + NVP
AZT +3TC + NVP
D4T + 3TC + EFV
TDF+3TC + EFV
AZT +3TC + EFV
TDF+3TC + NVP
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giving rise to ARV drug resistant HIV. When drug resistant mutations occur and or are 
transmitted, first line ARV drugs which are less costly and easier to administer are 
rendered ineffective.  Patients are required to be switched to second line drugs that are 
more costly, harder to administer and often associated with more side effects (NDTPAC 
& AIDS and TB Unit MOHCW 2010:10, 13) Switching from first line to second line ARVs 
can therefore give an indication that a patient has developed resistance to ARVs and or 
that the patient is not adhering to treatment.  ART regime switch is also indicated where 
drug interactions due to co-morbidities exist for example TB and pregnancy (NDTPAC & 
AIDS and TB Unit MOHCW 2010:27, 31-32), failure to control viral replication and side 
effects or toxicity. In resource poor settings, failure to maintain patients on first line 
regimens is a serious public health problem where issues of access and supply are also 
a challenge, further highlighting the importance of ART adherence.  In these settings it 
is especially important for patients to remain on first line treatment as long as possible, 
to ensure sustainability of ART programs (NDTPAC & AIDS and TB Unit MOHCW 
2010:5, 7, 21). 
 
Table 4.6:  Type and frequency of regimen “switch” 
 
 
Data from this study is encouraging in that it shows that during the follow-up period 
84.8% (n=100) remained on their original regimens and did not switch within the first-
line regimens (Table 4.6).  This is a statistically significant finding (p=0.009), suggesting 
that for the majority of the patients ARV drug resistance was being prevented and or 
that patients were adhering to their treatment. Most of the regimen changes that 
occurred 15.2% (n=18) were within first line drugs and mostly a change in the NNTRI 
drug (refer to Table 4.8, ARV drug classifications).  This is in-line with the guidelines for 
antiretroviral therapy in Zimbabwe which recommends substitution of suspected drug 
causing toxicity and or adverse events with an alternative same class drug within first 
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line regimen and only resort to second line drugs where treatment failure has been 
indicated (NDTPAC & AIDS and TB Unit MOHCW 2010:24-25).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Frequency of reasons for ART regimen switch among 18 
participants 
 
As indicated in figure 4.6, the main causes for the switches that occurred were either a 
new TB diagnosis (31%) or toxicity/side effects (31%) followed by pregnancy (23%). 
Immunological failure was indicated 7%, as reason for switch, 4% for clinical failure and 
another 4% indicated other and or were not recorded. Only 1 patient (0.8%) switched 
from first-line regimen to second-line.  Records of the only true switch in this study 
indicate that the patient also had TB and reasons indicated for the switch were that the 
patient was failing clinically and immunologically.  
 
The time it took from ART initiation to “switching” ART regimen varied among the study 
participants, figure 4.7 and was calculated by subtracting the date the participant was 
initiated on ART from the date the participant had ART regimen changed.  The mean 
time it took for participants in this study to “switch” their ART regimen was 215 days 
(slightly over 7 months) with a range of 13 to 433 days.  
 
4% 
7% 
31% 
23% 
31% 
4% 
Frequency of reasons for ART regimen 
switch 
Clinical failure
Immunological failure
Toxicity/side effects
Pregnancy
New TB diagnosis
Other
 
74 
 
Figure 4.7: Time between ART initiation and “switch” 
 
4.3.2.6 Subsequent follow-up dates of pharmacy refills  
 
The national ART treatment guidelines recommend that patients initiated on ART are 
prescribed an ARV regimen starter pack and seen every weeks for the first month (i.e. 2 
weeks + 2 weeks) to facilitate the close monitoring of ART adverse events (NDTPAC & 
AIDS and TB Unit MOHCW 2010:22-23, 45).  Once cleared of adverse events and or 
side effects, the treatment guidelines recommend that patients are reviewed monthly for 
the first three months and three monthly thereafter.  
 
For this study, the actual date of prescription re-fill and date of next appointment were 
recorded. Figure 4.8 shows a date profile of the first two pharmacy refills which shows 
that the majority of the participants were prescribed ART according to the treatment 
guidelines as described above.  Of the participants, 71% collected both their first 2 
weeks and second two weeks (1 month) within 14 days respectively.  The data also 
shows that another 16% although collection was on time (within 1 month), the number 
of days varied from 15 days to 28 days.  A total of 13% collected their prescription refills 
outside the acceptable range of days, with 2% of these participants having failed to 
collect their first month re-fills by more than 70 days.    
 
0
100
200
300
400
500
2
0
0
9
A
0
2
1
7
1
2
0
0
9
A
0
2
1
7
9
2
0
0
9
A
0
2
3
6
8
2
0
0
9
A
0
2
1
8
0
2
0
0
9
A
0
2
1
9
5
2
0
0
9
A
0
2
3
3
5
2
0
0
9
A
0
2
6
2
0
2
0
0
9
A
0
2
7
3
1
2
0
0
9
A
0
2
6
9
0
2
0
0
9
A
0
2
7
6
1
2
0
0
9
A
0
2
9
5
0
2
0
0
9
A
0
2
7
5
9
2
0
0
9
A
0
2
7
1
3
2
0
0
9
A
0
2
5
0
2
2
0
0
9
A
0
2
3
5
1
2
0
0
9
A
0
2
3
5
7
2
0
0
9
A
0
2
4
3
1
2
0
0
9
A
0
2
1
6
7
407 
257 
100 
268 
21 
433 
369 
17 
343 
13 55 
358 
308 
179 201 
369 
129 
36 
N
u
m
b
e
r 
o
f 
d
ay
s 
Participant ID 
Time between ART initiation and 
"switch" 
 
75 
 
Figure 4.8: First 2 follow-up dates of pharmacy refills after ART initiation 
 
4.3.2.7 Pharmacy refills adherence data 
 
As discussed in chapter 2, section 4.3.2.7 pharmacy refill data has the potential of being 
used in real time to manage and monitor HIV positive patients’ behaviour around taking 
ART to monitor adherence. Due to the high rate of HIV replication, high adherence 
levels of >95% are required for effective and sustained virologic suppression of the 
virus. Non-adherence to ARVs for HIV has major public health implications because of 
the emergence of drug-resistant viruses that can be transmitted to others and in the 
process diminishes future treatment options at population level.  Adherence to ART 
treatment programs recommend that adherence should be assessed on a regular basis 
in order to ascertain the level of adherence interventions needed for maintenance and 
or improvement of adherence levels. Pharmacy refill data was used to ascertain 
adherence levels for patients initiated on ART between 1 October 2009 and 31 
December 2009 and followed up for at least 12 months.   
 
In this study, adherence level was based on the actual date of prescription re-fill thus 
subtracting the actual day of prescription re-fill from the date of next appointment. The 
researcher believes this approach takes into account dynamic individual patient 
circumstances involved in the management of the HIV disease.  A seven day grace 
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period was applied across for all participants not collecting their prescriptions on the 
exact date of the next appointment.  If a patient however collected their prescription 
earlier than the date of the next appointment, these were considered adherent and or 
on-time collections.  
 
Data on pharmacy refills in this study showed that 62.7% (n=74) of the 118 patients 
managed to adhere (>95% adherence level) to their ARV regimens. A total of 44 
patients (37.3%) had adherence levels of <95% fiigure 4.9).  
 
 
Figure 4.9: Adherence levels as measured by pharmacy refill 
 
4.3.2.8 CD4 cell count  
 
One of the guidelines for ART initiation is a baseline CD4 count done on or before ART 
initiation  to establish how advanced the HIV disease is in a patient.  According to the 
national ART treatment guidelines and as already discussed in chapter 2, ART initiation 
is indicated for patients in (1) WHO stage III or IV disease irrespective of CD4 cell count 
for pregnant women, (2) HIV positive patients with CD4 cell count ≤350 cells/mm3 
regardless of WHO staging or 3) HIV positive with active tuberculosis (TB) irrespective 
of CD4 count for pregnant women (NDTPAC & AIDS and TB Unit MOHCW 2010:14-15, 
30).  The national ART treatment program, therefore utilises the CD4 cell count to 
inform eligibility for ART initiation and subsequently for patient management. The 
Immune system’s response to ART is monitored by measuring CD4 cell count six 
monthly and is expected to rise adequately to support normal immune function 
(NDTPAC & AIDS and TB Unit MOHCW 2010:50, 52). Good immunological response is 
<95%(Non-adherent) >95% (Adherent)
37.3% 
62.7% 
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expected when an HIV positive patient is adhering to treatment ≥95% of the time and 
this is indicated by a rise in the CD4 cell count (Paterson et al 2000:25).  
 
Equally important and as already discussed, patients are also initiated on ART based on 
their WHO HIV/AIDS clinical staging. During this study period, patients at Mpilo OI/ART 
clinic were initiated on ART according to the national guidelines that of CD4 cell count 
below 200 cells/mm3 or WHO HIV/AIDS clinical stages I, II and clinical stages III and IV 
irrespective of the CD4 cell count.  The inclusion criteria for this study required a 
participant to have a baseline CD4 cell count done on or before ART initiation, hence 
patients initiated on ART based only on WHO clinical stage were excluded. 
 
Data on CD4 cell counts at or before ART initiation and WHO HIV/AIDS clinical staging 
showed a corresponding CD4 cell count decrease from primary HIV infection/disease to 
advanced HIV disease.  The median CD4 cell count decreased consistently with the 
advancing stages of HIV infection with Stage I 208, Stage II 154, Stage III 149 and 
Stage IV 46 (figures 4.10 and 4.11).    
 
 
Figure 4.10:  Progressively lower CD4 cell count with advancing HIV infection  
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Figure 4.11:  CD4 cell count interquartile ranges by WHO clinical stage 
 
CD4 cell count in healthy persons range between 500-1500 cells/mm3 as already 
discussed and generally the more advanced the HIV disease is, the lesser the CD4 cell 
count.  CD4 cell count in many resource poor settings is also used to monitor treatment 
response with some researchers cautioning on its sole usage for this purpose (Charles 
et al 2012:5) citing retrospective identification of virological failure (Bisson et al 
2008:0786) and lack of specificity which could risk delaying treatment switch especially 
for those patients failing on first-line regimes (Charles et al 2012:5, Bisson et al 
2008:0786).  Despite this and as already mentioned, CD4 cell count still plays a major 
role in treatment monitoring in many resource poor countries. 
 
Table 4.7:  Baseline CD4 cell count at or before ART initiation 
Characteristics Category Total % 
Baseline CD4 count (cells/mm3) <100 42 35.6 
 
<200 36 30.5 
 
<350 35 29.7 
 
≥350 5 4.2 
Total 
 
118 100.0 
 
Data for this study show that 78 (66.1%) of the participants had less than 200 cells/mm3 
when they were initiated on ART (Table 4.7).  Overall 95.8% of the participants were 
initiated with a CD4 cell count less than 350 cells/mm3.  The mean baseline CD4 cell 
count for the participants in this study was 157.5 cells/mm3.  For all patients, the lowest 
baseline CD4 cell count was 2 cells/mm3 and the highest 667 cells/mm3.   
 p25  CD4   p50  CD4  p75  CD4
Stage I 145 208 302
Stage II 98 154 274
Stage III 86 149 220
Stage IV 14 46 100
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4.3.2.8.1 CD4 cell count during the follow-up period  
 
It is important to stress that National treatment and monitoring recommendations both 
previous and current, strongly recommend viral load testing but in the absence of 
virologic monitoring, persistent CD4 cell count below 100 cells/mm3 or a decrease in 
CD4 cell count below pre-therapy or a 50% CD4 cell count decrease is often used to 
identify immunologically failing patients (Charles, Leger, Sever, Guiteau, Apollon, 
Gulick, Johnson, Pape & Fitzgerald 2012:1; NDTPAC & AIDS and TB Unit MOHCW 
2010:54). In this study and as already described, a successful CD4 cell gain or 
immunological recovery was defined by a CD4 cell count gain of 50% or greater after 
ART initiation.  
 
Follow-up CD4 cell count after of ART initiation for this study showed that the lowest 
count was 14 cells/mm3 and highest 755 cells/mm3, with a mean CD4 cell count of 
368.1 cells/mm3.  Results of this study also showed that 97 (82.2%) of the study 
participants had successful 50% or greater CD4 cell count gain compared to 21 (17.8%) 
who failed to gain CD4 cell count by 50% or greater.  Figure 4.12 shows CD4 cell count 
at or before ART initiation and the follow-up CD4 cell count.  Analysis showed that there 
was a positive and statistically significant correlation between CD4 cell count at or 
before ART initiation and CD4 cell count during the follow-up period (r=0.46, p=<0.001).   
 
 
Figure 4.12: CD4 cell count at or before ART initiation and follow-up 
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4.3.3 Discussion of results  
 
4.3.3.1 The level of adherence to ART when measured by pharmacy refills 
compared to CD4 cell count  
 
Data on pharmacy refills in this study showed that 62.7% (n=74) of the 118 participants 
managed to adhere (>95% adherence level) to their ART regimens.  A total of 44 
participants (37.3%) were non-adherent when measured by pharmacy refills, with 
adherence levels of <95%.  Looking at CD4 cell count, 97 (82.2%) of the study 
participants had successful 50% or greater CD4 cell count gain suggesting that they 
were adherent to their ART regimens.  Of the participants, 21 (17.8%) failed to gain 
CD4 cell count by 50% or greater suggesting that they were not adhering to their ART 
regimens.   
 
In the follow-up period after ART initiation, data for this study showed that 15.1% (n=11) 
participants who were adherent by pharmacy refills did not have successful 50% CD4 
cell count gain after 1 year of ART (Table 4.8). A total of 10 (22.7%) participants were 
not adherent by pharmacy refills and did not have successful CD4 cell gain of 50%.  A 
total of 63 (84.9%) participants who were adherent also had a successful CD4 cell 
recovery or gain of 50% after ART initiation.  The data also showed that 34 (35.4%) 
were non-adherent by pharmacy refills but had successful CD4 cell count gain of 50% 
or higher.  Overall the data showed that there was no statistical significance (p=0.296) 
between adherence status when measured by pharmacy refill and CD4 cell count. 
 
Table 4.8: Pharmacy refill adherence vs 50% CD4 cell count gain 
Adherence 
NO YES Total (%) 
50% CD4 cell 
count gain 
NO 10 (22.7%) 11 (15.1%) 21 (17.95) 
YES 34 (77.3%) 63 (84.9%) 97 (82.05) 
Total (%) 44 (37.6%) 74 (62.4%) 118 (100) 
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4.3.3.2 The relationship between adherence to ART when measured by 
pharmacy refills and CD4 cell count   
 
Several studies have reported better outcomes for HIV/AIDS patients achieving good 
adherence levels to their ARVs in terms of better immunological response/recovery 
(increase in CD4 cell count) (Mocroft et al 2007:411; Paterson et al 2000:27), good 
virological response indicated by lower viral load (Paterson et al 2000:27  Nachega et al 
2007:566, Bisson et al 2008;0786), marginally lower morbidity and mortality rates 
(Paterson et al 2000:27-28,  Nachega et al 2006:82, Wood et al 2004:261) and reduced 
risk of developing HIV drug resistance (Nachega et al 2007:570, Wood et al 2004:261).  
As already discussed, the cohort for this study was initiated on ART based on a CD4 
cell count below 200 cells/mm3 and WHO HIV/AIDS clinical staging as stipulated in the 
national treatment strategy and guidelines.  
 
Results for this study using logistic regression analysis in a univariate model although 
not statistically significant, showed that participants who were adherent by pharmacy 
refills were 1.66 times more likely to gain 50% CD4 cells within the first year of ART 
initiation (OR=1.66, p=0.299) compared to those who were not adherent.   
 
Table 4.9: Multivariate analyses of 50% CD4 cell gain in patients on ART 
50% CD4 gain 
Odds 
Ratio 
95%CI 
p-
value 
Adherence 2.04 (0.70-5.90) 0.189 
Sex 3.26 (0.77-13.7) 0.108 
Age 0.94 (0.89-0.10) 0.048 
WHO Stage II 3.12 (0.51-19.2) 0.218 
WHO Stage III 2.11 (0.50-8.85) 0.309 
WHO Stage IV 10.07 (0.80-126.2) 0.073 
 
In multivariate analyses, covariates of adherence, sex, age and WHO clinical stage II, III 
and IV were included (Table 4.9). Participants who were pharmacy refill adherent were 
2.04 times more likely to gain 50% CD4 cells within the first year of ART (OR=2.04, 
p=0.19) compared to non-adherent participants although this was not statistically 
significant.  The odds of gaining 50% CD4 cells were 3.1 times higher for the female 
participants (OR=3.26, p=0.11) when compared to their male counterparts.  This 
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however was not statistically significant.  Looking at age the odds of gaining 50% CD4 
cells goes down by 0.06 with increase in age (OR=0.94, p=0.048).   In the model, as the 
WHO clinical stage increases, the odds of 50% CD4 cell gain increased with those 
participants  in WHO clinical stage IV at ART initiation being10.1 times more likely to 
gain  50% CD4 cells within the first year of ART than those in stage I (OR=10.07, 
p=0.073).   
 
 As presented earlier, mean CD4 cell count according to WHO clinical stage I, II, III and 
IV were 218.3, 164.3, 159.8 and 89.7 respectively, clearly pointing to more 
immunocompromised patients being in stage IV.  According to Mocroft et al (2007:410), 
patients initiating ART with relatively lower CD4 cell count, are more likely to show a 
greater CD4 cell count gain compared to those initiated with higher CD4 cell counts.  
The rate increase or gain of CD4 cell within the first year of ART initiation is also 
associated with previous virological failure (Bisson 2008:0780, Trotta, Cozzi-Lepri, 
Ammassari, Vecchiet, Cassola, Caramello, Vullo, Soscia, Chiodera, Ladisa, Abeli, 
Cauda, Buonuomi, Antinori Monforte 2010:462).  
 
Data from an Italian study indicated that CD4 cell gain is compromised if the patient has 
a history of virologic failure compared to those who had no history of virologic failure 
(Trotta et al 2010:462).  In earlier studies Wood et al (2004:266) showed that baseline 
CD4 cell count do not influence how quickly CD4 cell counts respond following ART 
initiation but adherence does.  Further, in the same study adherence was the strongest 
predictor of good immune recovery and sustained CD4 cell count gain (Wood et al 
2004:263-266).  
 
A cross-sectional study in Nigeria, Tanzania, Uganda and Zambia among 2344, found a 
direct association between patients with CD4 cell count less than 200 cells/mm3 and 
non-adherence (Memiah et al 2013:5).  In that study patients were reported to having 
high depression levels which may have led patients  to self-neglect, hopelessness and 
forgetfulness, cascading to non-adherence leading to low CD4 cell count and potentially 
early mortality (Memiah et al 2013:4-5). Studies have also shown that substantial and 
rapid increase in CD4 cell count happens in the first few months after ART initiation 
followed by a gradual but slower rate of increase after a year and subsequent years 
(Smith et al 2003:966-967, Smith et al 2004:1862-1863, Mocroft, Phillips, Gatell, 
Ledergerber, Fisher, Clumeck, Losso, Lazzarin, Fatkenheuer, Lundgren 2007:410).  In 
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one study, 237 patients were followed prospectively and the authors showed an overall 
median 197 cells/mm3 CD4 cell increase in the first year and a median 97.2 cells/mm3 
CD4 cell increase in the first month of HAART initiation. This was followed by a 
significant slowing down in the rate of CD4 cell increase in the following months to 1 
year with similar trends observed for year 2 (median CD4 cell increase of 92 cells/mm3) 
and an even slower rate of increase (CD4 cell median 50 cells/mm3 ) to year 3 (Smith et 
al 2003:967). The key element to the observed continual and sustained immunological 
recovery in these studies was the ability of the patients to adhere to HAART and thus 
effectively supress viral replication. 
 
4.4 CONCLUSION  
 
ART adherence levels assessed by pharmacy refill data, a non-immunological ART 
adherence parameter at Mpilo Hospital OI/ART clinic together with CD4 cell count, an 
immunological adherence measurement parameter have been presented in this 
chapter.  Socio-demographic data of the study participants is presented.  Pharmacy 
refill adherence levels have been analysed against  CD4 cell counts. Linkage of study 
findings to results of other published studies has been presented.     
 
The next chapter presents a summary of the study, highlights some limitations of this 
study and makes recommendations for future research. 
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CHAPTER 5 
 
SUMMARY FINDINGS, CONCLUSIONS AND RECOMMENDATIONS 
 
 
5.1 INTRODUCTION 
 
The summary of the study findings is presented in this chapter.  This chapter also 
discusses the study limitations, makes some recommendations and suggests possible 
further research. 
 
5.2 RESEARCH DESIGN AND METHOD  
 
The aim of the study was to determine the level of adherence to ART when using 
pharmacy refills and the extent of the relationship between ART adherence when 
measured by pharmacy refills and immunological parameters of CD4 count and HIV-1 
RNA levels (viral load) among HIV positive patients at Mpilo Central Hospital, 
Zimbabwe. The objectives of the study were to describe the level of adherence to ART 
when measured by pharmacy refills compared to CD4 cell count and viral load and the 
relationship between adherence to ART when measured by pharmacy refills and CD4 
cell count and viral load.   
 
A non-experimental, quantitative, retrospective, descriptive and correlational design was 
followed to achieve the study objectives using a probability sampling to select HIV 
positive adult patients initiated on ART between 1 October 2009 and 31 December 2009 
and followed up for 12 months at Mpilo Central Hospital. The rationale was to choose 
the latest recruits who were likely to present the current trends rather than older 
patients. The cohort date range chosen by the researcher took into consideration a 
period during which the Zimbabwean economic landscape had “normalised” after a 
serious economic downturn in the preceding three to four years.  The other factor also 
considered was finding a patient cohort that had completed a year on ART and were 
likely to have all their records complete by the time of conducting the study. The 
researcher readily had access to all records (n=118) of patients who met the inclusion 
criteria.  The sample size of 118 was found to be manageable and adequate for 
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quantitative data analysis. As a result no sampling procedures were applied for this 
study. Stata SE release 10 (STATA Corp, 2007) was used to analyse data.  
 
5.3 SUMMARY AND INTERPRETATION OF RESEARCH FINDINGS  
 
A total of 118 patients were included in the study, 67.8% of which were male and 32.2% 
female. The study participants’ ages ranged from 18 to 71 years, with a mean age of 
36.9.  At ART initiation, the majority of participants (59.3%) were married,   16.1% were 
single, 13.6% were widowed, 1.7% was divorced, 7.6% were separated and 1.7% did 
not have marital status recorded. Close to two thirds 69.5% of the study participants 
were unemployed, 7.63% were self-employed, 19.5% were formally employed 1 
participant was a student, 1 participant was employed in the private sector and 3 
participants did not have employment status recorded.  Most of the participants (44%) in 
this study lived in rented accommodation or lived with a relative, 39.9% owned the 
residence they had at ART initiation and 16.1% participants did not have their type of 
residence recorded.   
 
The duration that participants in this study had learnt of their HIV status ranged from 5 
day to 5.7 years with a mean period of 6 months.  Most participants were initiated on 
ART within a year of knowing their status, 10% more than a year after knowing their 
status and 1 participant was initiated on ART close to 6 years after being tested HIV 
positive.  Duration of having known the HIV status could not the established for 22% of 
the participants because the date of HIV testing was not recorded.   
 
The main entry point or referral source for ART initiation in this study was due to illness 
or having being hospitalised (42.4%).  ANC referred 23.7% of the participant for ART 
initiation, VCT 11.9% and TB illness 5.1%.  Entry for ART treatment because either 
spouse/partner or child had tested HIV positive accounted for 8.5% and 6.8% of the 
participants respectively.  A very high proportion of the participants (81.4%) had a 
treatment supporter mostly close members of the family of spouses, siblings or parents. 
Only 1.7% of the participants were recorded as not having a treatment supporter and 
16.9% participants did not have treatment supporter data recorded. 
 
The Majority of the patients were referred for ART initiation after hospitalisation or 
illness (42.4%) compared to 11.9% for VCT as an ART entry point.  A large proportion 
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(69.5%) of the study population was unemployed, and (81.4%) of the patients had a 
treatment supporter and or had disclosed their HIV status.  Equally high was the 
proportion of patients having a spouse as a treatment supporter (39.8%).  
 
With regard to the clinical data, the majority of the participants initiated on ART in this 
study were classified as stage III according to the WHO clinical staging guidelines for 
HIV/AIDS for adults and adolescents. The study results showed that there were more 
non-adherent participants (52.2%) in stage II, although in totality no correlation between 
WHO HIV/AIDS stage and adherence was seen.  Participants in this study were initiated 
on ART according to national ART guidelines of two NRTIs and one NNRTI as first-line 
regimens. Majority of the participants (84.8%) remained on their original regimens with 
most regimen changes (15.2%) occurring within first-line drugs.  One true second-line 
switch was recorded for this study.   
 
 The level of adherence to ART when measured by pharmacy refills 
compared to CD4 cell count and viral load 
 
The study results showed that the level of adherence among ART initiated patients at 
Mpilo Central Hospital was 62.7% (>95%) compared to 37.3% non-adherent 
participants (<95%) when measured by pharmacy refills. Adherence to ART based on 
50% or greater CD4 cell gain showed that 82.2% of the participants were adherent 
compared to 17.8% who failed to gain CD4 cells by 50% or greater.  
 
 The relationship between adherence to ART when measured by pharmacy 
refills and CD4 cell count and viral load 
 
Data on CD4 cell count showed that there was a positive relationship between 
baseline/CD4 cell count at ART initiation and the follow-up CD4 cell count. There was 
however no significant difference in baseline CD4 cell count between adherent and non-
adherent patients.  A corresponding decrease in CD4 cell count from primary to 
advanced HIV disease was observed in this study. Multivariate analysis showed that 
patients who were adherent (pharmacy re-fill data) were 2.04 times more likely to gain 
50% CD4 cell count within the first year of ART (p=0.19) compared to non-adherent 
patients.  More immunocopromised patients (WHO clinical stage IV) at ART initiation 
were more likely to gain 50% CD4 cells within the first year of ART (p=0.073) compared 
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to more healthier patients. This finding would also seem to suggest that for those 
patients with relatively higher CD4 cell count at ART initiation, applying this criterion to 
assess adherence would be inappropriate because chances of gaining 50% CD4 cell 
count coming from a higher threshold would be highly unlikely.  As a result there is high 
potential for these patients to be misclassified as non-adherent.  
 
5.4 CONCLUSION  
 
The conclusion drawn from the findings was that, using a 50% CD4 cell count gain in 
the 1 year follow-up period from ART initiation showed that 84.9% of the patients who 
had a successful CD4 cell gain of 50% were also adherent based on pharmacy refill 
data.   
 
5.5 CONTRIBUTIONS OF THE STUDY 
 
According to the findings of the study, there was a positive, albeit weak relationship 
between adherence measured by pharmacy refills and CD4 cell counts; suggesting that 
pharmacy refills can be used routinely to measure adherence in settings where CD4 cell 
count and viral load assays are not available. Pharmacy refills may also be used as a 
screening tool for patients suspected of treatment failure to be referred for virological 
testing thus reduce the number of viral load tests done and inevitably the cost of 
providing this service.  
 
The low adherence levels data ascertained by this study highlight the need for more 
education on the importance of ART adherence and more accessible ART adherence 
monitoring tools and systems.  The information gained may help strengthen messages 
on prevention and or risk reduction for emergence of drug resistant HIV.   
 
5.6 RECOMMENDATIONS 
 
The recommendations emanating from the study are based on practice (to increase 
ART adherence rates) and research as it pertains to ART adherence.  
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5.6.1 Recommendations to increase adherence rates  
 
In order to increase and better monitor adherence at Mpilo Central Hospital OI/ART 
Clinic, the researcher makes the following recommendations: 
 
 Deploy a computerised patient data management system 
 
Extracting data from the different clinic registers to come up with an ART historical 
picture of patients at Mpilo Central Hospital OI/ART clinic was difficult and very time 
consuming.  Although most of the data was available, comprehensively aggregating it 
for efficient and real time patient adherence management would almost be impossible.  
Hence a single computerised data management system should be installed for effective 
and efficient management of patients.  As discussed in section 3.6.3.2, an electronic 
data capturing system supported by MSF Spain was successfully implemented at this 
OI/ART clinic before its departure in December 2010, giving evidence that deployment 
of a computerised patient data management system at Mpilo Central Hospital OI/ART 
clinic is feasible. 
 
Records reviewed for the cohort period of this study showed that different patient 
identification number systems were in use and some patient data including viral load 
results were being captured into an information system not easily accessible to the 
health care provider to use in patient management.  A computerised patient tracking 
system that has a robust patient identification system should be deployed, possibly with 
different modules depending on the type of care the patient is seeking at the clinic.  For 
example, a module that seeks to monitor adherence should be able to capture 
pharmacy refill dates, ARV regimen dispensed, duration of dosage such that when a 
patient identification number is entered into the system, all relevant information related 
to the patient’s behaviour and or history with regards to taking medication should be 
displayed.  Flagging systems prompting the health care worker should be incorporated 
into the system so that if for example a patient is not adequately adhering, the health 
worker is prompted to refer the patient for more focussed adherence counselling before 
another refill can be dispensed.  Equally important would be modules capturing 
adherence counselling that would document if there are any psychosocial issues that 
may have changed and can either adversely or positively affect adherence.  Further, a 
clinical module capturing data of the variables already included in the ART registers that 
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include side effects, opportunistic infections and other medical manifestations would be 
essential.  This real-time data entry capacity would be helpful in preventing multiple and 
at times redundant data capturing into different registers and or other electronic systems 
delinked to patient management.  Such a system would not only aid in increasing 
adherence rates but would in general improve the whole ART patient management by 
freeing up more time for the health worker to spend with the patient, increase health 
care worker appreciation and use of electronic data to better improve service provision, 
reduce burden of patient file retrieval and re-filing, reduce health worker burnout and 
equally important allow the patient to spend less time at the clinic (Jamal, McKenzie & 
Clark 2009:26,34; Thomspson, Hudson, Wick & Ballestas 2009:109-111). 
 
 Establish and implement a clear method of monitoring adherence 
 
Adherence level established using both pharmacy refill data and CD4 cell count is low 
at Mpilo OI/ART clinic. Whilst CD4 count continues to be used, this parameter as 
suggested by others may be measuring adherence in retrospect (Bisson et al 
2008:0786).  If a computerised ART patient management system is in place, pharmacy 
refill data would be an objective, readily available, real-time and cost effective way of 
proactively monitoring adherence. 
 
5.7 RECOMMENDATIONS FOR FURTHER STUDY 
 
Adherence to ART is a dynamic phenomenon which requires on-going research.  The 
researcher proposes further research as follows: 
 
 A prospective research design with more than 12 months follow-up period needs 
to be carried out at Mpilo Central hospital or other public health institutions in 
Zimbabwe, to examine and monitor adherence and associated risk factors over 
time.  Further, with this research approach, morbidity, mortality and retention in 
care as they relate to adherence can be better understood. 
 MoHCC of Zimbabwe now has a viral load testing algorithm in place for 
monitoring patients on ART.  Viral load testing is currently being conducted at 
one central laboratory in the capital of Zimbabwe Harare, with possible 
decentralisation to a few provincial laboratories in the near future. Samples 
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needing testing even with the decentralisation will require transportation and 
other logistical support, ultimately compromising on turn-around-time.  A cost 
effectiveness evaluation of the viral load testing algorithm in adherence 
monitoring compared to pharmacy refill data should be done.  Further, validation 
research of other non-immunological ART adherence measuring tools with viral 
load is needed. 
 Data on adherence in older HIV positive patients on ART in resource poor 
settings is sparse in literature.  In this study multivariate analyses seemed to 
suggest diminished ability to gain 50% CD4 with older aged patients although 
this was not statistically significant. This population would be of interest to study 
because in resource poor settings, this population is also caring for HIV and 
AIDS orphans.  So understanding their behaviour with regards to ARV treatment 
and adherence is important not only for their own health but also because in 
many cases they are also treatment supporters to orphaned children and other 
family members.  Research examining factors associated with ART adherence 
such as social disclosure, social support, depression and co-morbidities should 
be conducted. 
 
5.8 LIMITATIONS OF THE STUDY 
 
Limitations to this study include the following: 
 
 A small sample was used for this study and was limited to patients initiated on 
ART at Mpilo Central Hospital and thus may not be representative of all patients 
on ART in Zimbabwe. 
 This was a retrospective study and therefore not all eligible patients were 
included neither can causal inferences be made. 
 Viral load (HIV-RNA) is strongly recommended for monitoring patients on ART 
mainly for virological failure which would also indicate possible failure to adhere 
to treatment.  This parameter was part of the study aims and as already 
discussed this objective could not be adequately fulfilled. 
 Treatment strategies including pharmacy refill periods for patients were based on 
individual patient circumstances.  Some patients were given more than a month’s 
supply of drugs, thus assumptions are that for the 3 or 4 months prescription the 
patient was adherent and thus might overestimate the overall adherence rate. 
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 Patient records were not included in the analysis due to incomplete data.  
Majority of these were due to patients with no baseline CD4 cell count.  This was 
mainly due to the fact that patients may have been initiated on ARVs based on 
their WHO staging.  As reported in this study, majority of the patients initiated on 
ART were in WHO stage IV of the HIV disease. It is very possible that many 
patients were well advanced in their HIV disease that baseline CD4 cell count 
was not a critical requirement for deciding treatment and care of the patients.   
 The patient cohort for this study was recruited from an MSF supported site where 
HIV and AIDS dedicated physicians oversaw the OI/ART programme. 
Additionally, because of the extra funding that MSF provided for the running of 
the OI/ART program, patients seen in this health facility might have experienced 
less drug stock outs, had access to better health services and it is possible that 
they would have had higher adherence levels when compared to patients 
seeking the same services in similar government or public health facilities. 
 
5.9 CONCLUDING REMARKS  
 
This chapter presented a summary of the research findings, the conclusions reached on 
the basis of the findings, recommendations as well as the limitations of the study. 
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